var title_f33_23_34160="Nystatin: Pediatric drug information";
var content_f33_23_34160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nystatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12805652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/52/14147?source=see_link\">",
"       Nystatin (oral): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/24/16771?source=see_link\">",
"       Nystatin (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12654 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34160=[""].join("\n");
var outline_f33_23_34160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/52/14147?source=related_link\">",
"      Nystatin (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/24/16771?source=related_link\">",
"      Nystatin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34161="Intraluminal fulgaration of the vas during vasectomy";
var content_f33_23_34161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraluminal fulgaration of the vas during vasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A disposable cautery is used to fulgarate the lumen of the vas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &copy;1999 Timothy Clenney, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34161=[""].join("\n");
var outline_f33_23_34161=null;
var title_f33_23_34162="Eumycetoma foot B";
var content_f33_23_34162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eumycetoma tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beatriz Bustamante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34162=[""].join("\n");
var outline_f33_23_34162=null;
var title_f33_23_34163="Ascending colon TB enteritis";
var content_f33_23_34163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Ascending colon tuberculous enteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Colonoscopic view of circumferential ulcers involving the cecum and ascending colon due to tuberculosis.",
"    <br/>",
"    B) Colonoscopic view of longitudinal ulcers (arrows) involving the ascending colon due to Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harshad Devarbhavi, MD (image A) and Louis M. Wong Kee Song, MD (image B).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34163=[""].join("\n");
var outline_f33_23_34163=null;
var title_f33_23_34164="Sebaceous hyperplasia";
var content_f33_23_34164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sebaceous hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple yellowish papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34164=[""].join("\n");
var outline_f33_23_34164=null;
var title_f33_23_34165="Overview of nystagmus";
var content_f33_23_34165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nystagmus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Jason JS Barton, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34165/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/23/34165/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nystagmus is a",
"    <strong>",
"     rhythmic regular oscillation",
"    </strong>",
"    of the eyes. It may consist of alternating phases of a slow drift in one direction with a corrective quick \"jerk\" in the opposite direction, or of slow, sinusoidal, \"pendular\" oscillations to and fro. Jerk nystagmus is more common than pendular nystagmus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23658?source=see_link\">",
"     \"Jerk nystagmus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=see_link\">",
"     \"Pendular nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nystagmus can be continuous or paroxysmal, or evoked by certain maneuvers such as specific gaze or head positions. Nystagmus associated with some pathologies may only be seen transiently with hyperventilation or coughing and sneezing.",
"   </p>",
"   <p>",
"    An overview of nystagmus, its treatment, and the vestibular physiology relevant to nystagmus and vertigo is presented here. The approach to vertigo is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF NYSTAGMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the two major types of nystagmus are jerk nystagmus and pendular nystagmus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Jerk nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jerk nystagmus is subdivided by trajectory and the conditions under which it occurs (",
"    <a class=\"graphic graphic_table graphicRef72446 \" href=\"mobipreview.htm?10/40/10892\">",
"     table 1",
"    </a>",
"    ). Some forms are always present, even when the eyes are in the primary position. Nystagmus in the primary position is classified according to trajectory:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      downbeat",
"     </li>",
"     <li>",
"      upbeat",
"     </li>",
"     <li>",
"      horizontal",
"     </li>",
"     <li>",
"      torsional",
"     </li>",
"     <li>",
"      mixed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The direction named is the direction of the fast phase.",
"   </p>",
"   <p>",
"    Other forms emerge only under specific conditions such as peripheral gaze (gaze-evoked) and certain head positions (positional). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23658?source=see_link\">",
"     \"Jerk nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most acquired jerk nystagmus are the result of an asymmetry in vestibular inputs, in either the central or peripheral nervous system. Understanding the diagnostic value of the trajectory of jerk nystagmus requires some knowledge of the physiology of the semicircular canals (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pendular nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pendular nystagmus has a sinusoidal oscillation without fast phases. The waveform of pendular nystagmus may occur in any direction; it can be torsional, horizontal, vertical, or a combination of these, resulting in circular, oblique, or elliptical trajectories. It can be different in the two eyes, sometimes even monocular. A video demonstrating pendular nystagmus is available at",
"    <a class=\"external\" href=\"file://www.neuroophthalmology.ca/cases/case19/case19.html\">",
"     file://www.neuroophthalmology.ca/cases/case19/case19.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The diagnosis of pendular nystagmus is an exercise in pattern recognition, since pendular nystagmus is subdivided into a number of types recognized mainly by very specific trajectories. These are described in detail separately. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=see_link\">",
"     \"Pendular nystagmus\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired pendular nystagmus",
"     </li>",
"     <li>",
"      Congenital nystagmus",
"     </li>",
"     <li>",
"      Pendular nystagmus with visual loss",
"     </li>",
"     <li>",
"      Specific variants include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      spasmus nutans &nbsp;",
"     </li>",
"     <li>",
"      oculopalatal myoclonus",
"     </li>",
"     <li>",
"      see-saw nystagmus",
"     </li>",
"     <li>",
"      oculomasticatory myorhythmia (Whipple's)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC CLINICAL VESTIBULAR PHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The vestibular sensory organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two components to the peripheral vestibular system:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The otolithic organs",
"     </li>",
"     <li>",
"      The semicircular canals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The otolithic organs are the saccule and the utricle, each of which has a plane of hair cells embedded in a heavy slab of material containing calcium. These slabs have a significant amount of inertia. Any linear acceleration of the head (eg, gravity) causes the head to move relative to the otoconia, resulting in a bending of the hair cells and a change in neuronal activity.",
"   </p>",
"   <p>",
"    The semicircular canals detect angular accelerations (turns, or rotations) of the head. Each canal contains fluid and a gelatinous structure called the ampulla, in which hair cells are embedded. Rotation of the head causes the canal to move relative to the fluid within it, thereby generating a force against the ampulla that bends the hair cells. An increase or decrease from the baseline firing rate occurs depending upon the direction of rotation.",
"   </p>",
"   <p>",
"    There are six canals, two per side, arranged along three cardinal planes. The two horizontal canals lie in one plane, not quite horizontal but tilted downward 30 degrees. The vertical (anterior and posterior) canals are all at approximately right angles to the horizontal plane, but positioned in two planes 45 degrees from the sagittal plane. Thus, each plane has a pair of canals, the anterior canal of one side paired with the posterior canal of the other side.",
"   </p>",
"   <p>",
"    The vestibular system uses these pairs of canals in a \"push-pull\" reciprocal fashion. An angular movement of the head along one of these planes will maximally activate one canal and maximally inhibit its counterpart. Thus, the normal resting firing rate of the nerve from one canal increases while that of its counterpart decreases. The net change in both directions is summed algebraically by the brain to reveal the change in head position. This information is transmitted to the ocular motor nuclei, causing the eyes to move smoothly an equal and opposite amount to the head turn (the vestibuloocular reflex), enabling the eyes to remain stationary in space despite the head movement.",
"   </p>",
"   <p>",
"    The directions that excite each canal are given by a simple rule: \"a canal is excited by head motion towards the canal, in the appropriate plane.\" Thus, the right horizontal canal is excited by right head",
"    <strong>",
"     turns",
"    </strong>",
"    , the right posterior canal is excited by right head",
"    <strong>",
"     tilts",
"    </strong>",
"    or \"posterior\" head tilts (neck extension), and the left anterior canal is excited by left head tilts or \"anterior\" head tilts (neck flexion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vestibuloocular responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vestibuloocular reflex keeps the line of sight stable in space while the head is moving. Thus, it uses information about head rotation to drive the eyes an equal amount in the opposite direction. To accomplish this, each semicircular canal has excitatory projections to a pair of extraocular muscles, one in each eye, and inhibitory projections to an antagonistic pair. The muscles maximally activated by a canal are approximately aligned with the plane of that canal.",
"   </p>",
"   <p>",
"    To understand the effects of such activation requires knowledge of the direction of pull of each extraocular muscle. The horizontal recti are simple: the lateral recti abduct and the medial recti adduct the eye. The vertical recti and obliques are more complex: they all have primary, secondary, and tertiary actions upon the globe (",
"    <a class=\"graphic graphic_table graphicRef71408 \" href=\"mobipreview.htm?12/41/12955\">",
"     table 2",
"    </a>",
"    ). It is useful to think of the line of pull of these muscles as approximately aligned with the planes of the vertical semicircular canals. While the line of pull remains roughly constant, the effect of the pull upon the eye in part depends upon whether the eye is abducted or adducted at the time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contraction of the superior rectus elevates the eye, especially when it is in the abducted position. When the eye is adducted, however, this strong primary action of the muscle is less and there is also more of an intorsional motion.",
"     </li>",
"     <li>",
"      Contraction of the inferior rectus leads to the opposite pattern: depression of the eye in abduction with some extorsion in adduction.",
"     </li>",
"     <li>",
"      Contraction of the superior oblique causes mainly intorsion of the eye, as it pulls the top of the eye towards the pulley at the anteromedial corner of the roof of the orbit. This is maximal in abduction. When the eye is adducted, however, the pull of the top of the eye toward the pulley now causes depression.",
"     </li>",
"     <li>",
"      Contraction of the inferior oblique, whose origin is at the anteromedial corner of the floor of the orbit, leads to the opposite pattern, extorsion of the eye in abduction, with elevation in adduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With these data it is easy to see which pair of muscles is activated (or inhibited) by each semicircular canal to keep the line of sight steady with head turns (",
"    <a class=\"graphic graphic_table graphicRef61830 \" href=\"mobipreview.htm?29/8/29836\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Generation of nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the planes of action and ocular activations of the semicircular canals and their push-pull relationship with opposing canals on the other side is essential to understanding how jerk nystagmus is generated. With a lesion of the right horizontal canal, for example, there is a loss of tonic leftward vestibular input since there is always a baseline level of activity. The unopposed rightward \"push\" from the intact left horizontal canal creates a slow rightward drift of the eyes, the \"slow phase,\" which is eventually counteracted by a leftward fast phase. Thus, loss of the right horizontal canal creates left-beating nystagmus.",
"   </p>",
"   <p>",
"    Similarly, loss of the right anterior canal creates a nystagmus that is a mix of upbeat and counterclockwise torsional fast phases, and loss of the right posterior canal creates a",
"    <span class=\"nowrap\">",
"     downbeat/counterclockwise",
"    </span>",
"    torsional nystagmus. If all three canals on the right side are lost, the upbeat and downbeat components cancel each other out, but the counterclockwise torsional effect add together and summate with the left-beating horizontal nystagmus to create a mixed horizontal-torsional nystagmus. This is the typical finding with \"peripheral nystagmus,\" that is, nystagmus from acute unilateral damage to the labyrinth or vestibular nerve.",
"   </p>",
"   <p>",
"    This also explains why pure vertical nystagmus is rarely if ever generated by peripheral vestibular disease. To obtain pure downbeat nystagmus, a lesion would have to affect the two posterior canals, summating the resulting loss of upward slow drifts, canceling the opposing torsional drifts, and sparing all other canals. The odds are against such a selective yet bilateral lesion of the labyrinth. The same holds for pure upbeat nystagmus. On the other hand, the central vestibular pathways in the brainstem are organized so that such deficits are possible.",
"   </p>",
"   <p>",
"    Pure torsional nystagmus conceivably could result from a lesion that affected both the anterior and posterior canal on one side, sparing the horizontal canal. However, the regional blood supply and nerve subdivisions of the labyrinth segregate the anterior canal and horizontal canal from the posterior canal. Clinical studies suggest that vestibular neuronitis, for example, is a partial defect whose nystagmus suggests either a combination of horizontal and anterior canal dysfunction, or almost pure horizontal canal loss. Thus, partial lesions of the periphery are unlikely to cause pure torsional nystagmus. Pure horizontal nystagmus, however, could be either central or peripheral.",
"   </p>",
"   <p>",
"    Some nystagmus is the result of hyperfunction of a canal rather than hypofunction of one labyrinth. The classic example is benign paroxysmal positional vertigo. Movement of debris in the posterior canal leads to abnormal activation, generating slow downward and torsional drifts, and therefore a mixed",
"    <span class=\"nowrap\">",
"     upbeat/torsional",
"    </span>",
"    nystagmus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link\">",
"     \"Benign paroxysmal positional vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from vertigo, which is most prominent with acute unilateral peripheral vestibular disease, nystagmus can cause three main symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oscillopsia &mdash; Oscillopsia is a to-and-fro illusion of environmental motion. Depending upon the nystagmus, this may be continuous, intermittent, or gaze-evoked. This contrasts with the oscillopsia from bilateral vestibular hypofunction, which only occurs when the head is moving, as when walking or riding in a car.",
"     </li>",
"     <li>",
"      Blurred vision &mdash; Blurred vision occurs because the retinal image is smeared by stimulus motion.",
"     </li>",
"     <li>",
"      Abnormal head positions &mdash; Patients who find that their oscillopsia or blurred vision is least troublesome in certain gaze positions that minimize nystagmus may assume abnormal head positions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rhythmic nature and slow speeds of nystagmus distinguish it from a number of other abnormal involuntary eye movements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saccadic intrusions are irregular bursts of rapid eye movements, almost always indicating a problem of the cerebellum. These movements include opsoclonus, ocular flutter, square wave jerks, and macrosaccadic oscillations. Voluntary nystagmus is a misnomer; it too is a type of saccadic intrusion, which most resembles ocular flutter.",
"     </li>",
"     <li>",
"      Ocular bobbing and its variants have slow drifts and fast phases but are much more irregular than nystagmus. They usually occur in comatose individuals.",
"     </li>",
"     <li>",
"      Oculogyric crises are irregular prolonged deviations of the eyes, usually up and lateral, that lack rhythmicity and slow phases. They are most frequently encountered with phenothiazine intoxication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to nystagmus therapy involves three basic considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the type of nystagmus?",
"     </li>",
"     <li>",
"      Are there treatable underlying causes? Consider intoxications, metabolic derangements, infections, and operable structural lesions.",
"     </li>",
"     <li>",
"      What is the potential benefit of symptomatic treatment?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goals of improvement in the symptoms listed above (vertigo, oscillopsia, motion-degraded acuity, or head turn) should be clear prior to treatment. Patients without these symptoms do not require symptomatic treatment.",
"   </p>",
"   <p>",
"    There are four main types of symptomatic nystagmus therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medication",
"     </li>",
"     <li>",
"      Botulinum injections",
"     </li>",
"     <li>",
"      Prism lenses and optical solutions",
"     </li>",
"     <li>",
"      Surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate medication use depends upon the type of nystagmus. Proven drug therapies are only available for a few specific forms, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    for periodic alternating nystagmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/3\">",
"     3",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    for pendular nystagmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=see_link\">",
"     \"Pendular nystagmus\"",
"    </a>",
"    .) There are unproven anecdotal reports for many others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Botulinum injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum injections into muscle or the intraconal space have been used to weaken the extraocular muscles and diminish the amplitude of nystagmus. These improve vision, oscillopsia, and nystagmus somewhat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], but they also weaken normal eye movements. In some reports the most telling detail is that patients have declined to repeat the experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prism lenses and optical solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prism lenses and optical solutions may be useful in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If patients have a position of gaze in which nystagmus is minimal, prisms can be used so that the eyes are in this \"null position\" when the patient is trying to look directly ahead. Oscillopsia is thereby minimized for this most frequent gaze position, but gaze to the side will still bring on symptoms.",
"     </li>",
"     <li>",
"      If convergence dampens nystagmus, the patient can wear prisms that make the eyes more convergent while fixating in the distance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High hyperopic glasses can be combined with high myopic contact lenses to create a situation in which the retinal image does not shift with eye movement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. This is useful for reading, but the field of view narrows to a tunnel, and the desirable effects of normal eye movements are impaired in that they do not shift or steady gaze normally. Thus, the system cannot be worn while walking around. Most patients find the device cumbersome.",
"     </li>",
"     <li>",
"      Contact lenses can dampen congenital nystagmus for unknown reasons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surgery tries to shift the attachment of the muscles so that the muscle tensions appropriate to a gaze position where nystagmus was minimal or absent now place the eyes in center gaze. In essence, this is similar to the strategy of prism therapy and, as with prisms, oscillopsia will still be present in lateral gaze. Surgery has been used mainly with congenital nystagmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], where it has been reported to improve visual acuity in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34165/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7761320\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nystagmus is a rhythmic regular oscillation of the eyes. The rhythmic nature and slow speeds of nystagmus distinguish it from a number of other abnormal involuntary eye movements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jerk nystagmus occurs most often when there is an imbalance in the activation of the semicircular canals because of either peripheral vestibular disease or disruption of central vestibular pathways in the brainstem (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Generation of nystagmus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nystagmus may be associated with the clinical symptoms of vertigo, oscillopsia, abnormal head position,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blurred vision (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Jerk nystagmus consists of alternating phases of a slow drift in one direction with a corrective quick \"jerk\" in the opposite direction. It is further classified according to trajectory and the conditions under which it occurs (",
"      <a class=\"graphic graphic_table graphicRef72446 \" href=\"mobipreview.htm?10/40/10892\">",
"       table 1",
"      </a>",
"      )(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23658?source=see_link\">",
"       \"Jerk nystagmus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pendular nystagmus consists of slow, sinusoidal, \"pendular\" oscillations to and fro subdivided into a number of types recognized mainly by very specific trajectories (eg, acquired pendular nystagmus, congenital nystagmus, etc.) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=see_link\">",
"       \"Pendular nystagmus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment is symptomatic. Appropriate medication use depends upon the type of nystagmus. Prism lenses and other optical solutions and ocular surgery may be helpful in specific circumstances (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/1\">",
"      Kaminski HJ, Leigh RJ. International Symposium for Therapy of Ocular Motility and Related Visual Disturbances. Neurology 1997; 48:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/2\">",
"      Leigh RJ, Averbuch-Heller L, Tomsak RL, et al. Treatment of abnormal eye movements that impair vision: strategies based on current concepts of physiology and pharmacology. Ann Neurol 1994; 36:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/3\">",
"      Halmagyi GM, Rudge P, Gresty MA, et al. Treatment of periodic alternating nystagmus. Ann Neurol 1980; 8:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/4\">",
"      Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997; 41:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/5\">",
"      Helveston EM, Pogrebniak AE. Treatment of acquired nystagmus with botulinum A toxin. Am J Ophthalmol 1988; 106:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/6\">",
"      Leigh RJ, Tomsak RL, Grant MP, et al. Effectiveness of botulinum toxin administered to abolish acquired nystagmus. Ann Neurol 1992; 32:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/7\">",
"      Repka MX, Savino PJ, Reinecke RD. Treatment of acquired nystagmus with botulinum neurotoxin A. Arch Ophthalmol 1994; 112:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/8\">",
"      Tomsak RL, Remler BF, Averbuch-Heller L, et al. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol 1995; 119:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/9\">",
"      Lavin PJ, Traccis S, Dell'Osso LF, et al. Downbeat nystagmus with a pseudocycloid waveform: improvement with base-out prisms. Ann Neurol 1983; 13:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/10\">",
"      Traccis S, Rosati G, Monaco MF, et al. Successful treatment of acquired pendular elliptical nystagmus in multiple sclerosis with isoniazid and base-out prisms. Neurology 1990; 40:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/11\">",
"      Rushton D, Cox N. A new optical treatment for oscillopsia. J Neurol Neurosurg Psychiatry 1987; 50:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/12\">",
"      Yaniglos SS, Leigh RJ. Refinement of an optical device that stabilizes vision in patients with nystagmus. Optom Vis Sci 1992; 69:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/13\">",
"      Abadi RV. Visual performance with contact lenses and congenital idiopathic nystagmus. Br J Physiol Opt 1979; 33:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/14\">",
"      Dell'Osso LF, Flynn JT. Congenital nystagmus surgery. A quantitative evaluation of the effects. Arch Ophthalmol 1979; 97:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/15\">",
"      ANDERSON JR. Causes and treatment of congenital eccentric nystagmus. Br J Ophthalmol 1953; 37:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34165/abstract/16\">",
"      D'Esposito M, Reccia R, Roberti G, Russo P. Amount of surgery in congenital nystagmus. Ophthalmologica 1989; 198:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5109 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34165=[""].join("\n");
var outline_f33_23_34165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7761320\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF NYSTAGMUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Jerk nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pendular nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC CLINICAL VESTIBULAR PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The vestibular sensory organs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vestibuloocular responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Generation of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Botulinum injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prism lenses and optical solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7761320\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/40/10892\" title=\"table 1\">",
"      Classification of jerk nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/41/12955\" title=\"table 2\">",
"      Function extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/8/29836\" title=\"table 3\">",
"      Canaliculoocular reflexes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23658?source=related_link\">",
"      Jerk nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=related_link\">",
"      Pendular nystagmus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34166="Sinoatrial nodal reentrant tachycardia (SANRT)";
var content_f33_23_34166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sinoatrial nodal reentrant tachycardia (SANRT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Munther K Homoud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34166/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/23/34166/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardias have traditionally been characterized as automatic, triggered, or reentrant. However, the European Society of Cardiology and the North American Society of Pacing and Electrophysiology in 2001 proposed a classification that takes into consideration both anatomic features and electrophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/1\">",
"     1",
"    </a>",
"    ]. Atrial tachycardia is the overriding term that includes two major categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal atrial tachycardia due to an automatic, triggered, or microreentrant mechanism",
"     </li>",
"     <li>",
"      Macroreentrant atrial tachycardia, including typical atrial flutter and other well-characterized macroreentrant circuits in the right and left atrium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sinoatrial nodal reentrant tachycardia (SANRT), also called sinus node reentry or sinus node reentrant tachycardia, falls into the latter group of macroreentrant arrhythmias. This topic will discuss the mechanisms, clinical manifestations, and treatment of SANRT. Discussions of other specific atrial arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=see_link\">",
"     \"Intraatrial reentrant tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13137656\">",
"    <span class=\"h1\">",
"     DEFINITION AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially described in the 1940s, SANRT has often been considered a form of atrial tachycardia. However, SANRT has an activation sequence similar to that of normal sinus rhythm so that the P waves on the surface ECG appear to be normal. In comparison, intraatrial reentry has a different activation sequence of atrial depolarization, leading to a P wave morphology that differs from that of normal sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=see_link\">",
"     \"Intraatrial reentrant tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the electrophysiologic features that distinguish SA nodal reentrant tachycardia and other reentrant atrial rhythms (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"mobipreview.htm?38/33/39441\">",
"     figure 1",
"    </a>",
"    ) from automatic and triggered atrial tachycardias are summarized (",
"    <a class=\"graphic graphic_table graphicRef53347 \" href=\"mobipreview.htm?6/56/7052\">",
"     table 1",
"    </a>",
"    ). The exact mechanism of SA nodal reentry is not known; however, three possibilities have been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/2\">",
"     2",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reentry occurring entirely within the SA node, based primarily on one animal study in which the reentrant pathway was localized within the SA node [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reentry involving the SA node and perinodal tissue, based on a number of studies that have suggested the reentrant loop involves more than the SA node [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/2,4-6\">",
"       2,4-6",
"      </a>",
"      ]. What we call the SA node is actually the integrated activity of pacemaker cells in the compact region of the SA node [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/7\">",
"       7",
"      </a>",
"      ]. These several thousand cells depolarize and produce action potentials almost synchronously and seem to influence each other through cell-to-cell coupling, a process that has been called \"mutual entrainment\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reentry using the SA node as the refractory center around which reentry occurs, although there is limited evidence for this potential mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reentry with the SA node only or the SA node and perinodal tissue is the most likely mechanism of SANRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;SANRT, an uncommon arrhythmia that rarely causes symptoms, occurs most commonly in adults and children who have structural heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In patients with supraventricular tachycardia referred for electrophysiologic study, estimates of the frequency of SANRT have ranged from 2 to 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. However, approximately 10 to 15 percent of patients who undergo electrophysiologic studies for symptomatic atrial tachycardia have sinus nodal echoes (single or multiple reentrant beats that utilize the SA node), indicating the presence of a substrate for SA nodal tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. In addition, the actual incidence of this arrhythmia may be higher than appreciated since many patients are asymptomatic and do not come to electrophysiologic study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771727\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the clinical manifestations and significance of SANRT are minimal. Most patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. Symptoms, when present, tend to start and stop abruptly. If a patient is examined during an episode of arrhythmia, he or she will have a regular heart rate greater than 100 beats per minute. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of palpitations in adults\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most episodes of SANRT do not precipitate hemodynamic compromise or limiting symptoms. However, on rare occasions, SANRT can be sufficiently recurrent, rapid,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sustained to be symptomatic. Higher ventricular rates associated with SANRT in a patient with underlying advanced cardiac or pulmonary disease can sometimes exacerbate their disease, leading to signs and symptoms of angina, heart failure, or worsening systemic oxygenation.",
"   </p>",
"   <p>",
"    In the face of persistently elevated ventricular rates (eg, for weeks to months), particularly if baseline ventricular dysfunction exists, heart failure (tachycardia-mediated cardiomyopathy) may ensue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13137664\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SANRT should be considered in the presence of a regular but rapid pulse and heartbeat on physical examination. The electrocardiogram (ECG) will show P waves with a rate between 100 and 150 beats per minute. Given that the P waves are virtually identical to those observed in sinus rhythm, patients may often be thought to have inappropriate sinus tachycardia. In most cases, the diagnosis of SANRT cannot be confirmed without invasive electrophysiologic studies. Vagal maneuvers and adenosine can sometimes help as either will slow the tachycardia before the arrhythmia is abruptly terminated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link&amp;anchor=H6#H6\">",
"     \"Sinus tachycardia\", section on 'Inappropriate sinus tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While pursuing invasive testing to make the diagnosis is not generally necessary, when symptoms are present clinically or the arrhythmia appears incessant, it is important to distinguish SANRT from other supraventricular tachycardias (SVT). In a patient with sustained tachycardia and reduced left ventricular function in whom tachycardia-mediated cardiomyopathy is a consideration, we would suggest more aggressive efforts at confirming or excluding SANRT as the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771806\">",
"    <span class=\"h2\">",
"     Electrocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, SANRT has an activation sequence similar to that of normal sinus rhythm. (See",
"    <a class=\"local\" href=\"#H13137656\">",
"     'Definition and mechanisms'",
"    </a>",
"    above.) Thus, the surface ECG has P waves that are virtually identical to those observed in sinus rhythm and often will be interpreted as a sinus tachycardia. The abrupt onset and termination of the arrhythmias can aid clinically in differentiating SANRT from sinus tachycardia.",
"   </p>",
"   <p>",
"    Conduction through the AV node, the specialized infranodal conduction system (His bundle, fascicles and bundle branches, terminal Purkinje fibers), and the ventricles also should be similar to normal AV conduction unless the rapid rate causes some type of functional conduction disturbance (ie, rate-related bundle branch block). The rate in SANRT is usually between 100 and 150 beats per minute. Episodes vary in length, lasting anywhere from seconds to hours.",
"   </p>",
"   <p>",
"    The response to vagal maneuvers can aid in differentiating sinus tachycardia (gradual slowing in response to vagal stimulus) from SANRT (abrupt termination of the arrhythmia). Patients should undergo continuous ECG monitoring during the vagal maneuvers. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Autonomic maneuvers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Electrophysiologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, when symptoms are present or the arrhythmia appears incessant, it is important to distinguish SANRT from other supraventricular tachycardias (SVT), particularly focal atrial tachycardia. Since the surface electrocardiogram alone is not reliable in distinguishing SANRT from other types of SVT, invasive electrophysiological studies (EPS) can be employed to help make this distinction. Since macroreentrant atrial arrhythmias, including SANRT, are reentrant, they can be entrained during EPS with manifest and concealed fusion, and upon cessation of atrial pacing, the post pacing interval should be within 30 milliseconds of the tachycardia cycle length if pacing is performed within the reentrant pathway. The use of newer mapping techniques such as electroanatomical mapping further helps to make this distinction where focal mechanisms display centrifugal activation patterns, reentry displays an \"early meets late\", and the entire cycle length of the tachycardia can be mapped to the chamber containing the tachycardia. The initiation with premature atrial beats independent of intraatrial or AV nodal conduction delays or, better yet, in the presence of AV block, helps confirm the diagnosis. The P wave morphology is identical to sinus node P wave morphology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SA nodal reentrant tachycardia can be initiated by atrial premature beats, atrial pacing, and, unlike intraatrial reentry, by ventricular premature beats and ventricular pacing with retrograde VA conduction. The rarity of induction of intraatrial reentry by a ventricular premature beat is due to the delay in retrograde VA conduction which limits the prematurity with which the premature beat can depolarize the atrium. Neither the AV node nor a bypass tract is a necessary part of the circuit. The reentrant circuit can be penetrated and reentry aborted by premature atrial depolarizations or atrial pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13137688\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block) and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial flutter",
"     </li>",
"     <li>",
"      Atrioventricular reciprocating tachycardia",
"     </li>",
"     <li>",
"      Focal atrial tachycardia",
"     </li>",
"     <li>",
"      Sinoatrial nodal reentrant tachycardia",
"     </li>",
"     <li>",
"      Sinus tachycardia, including inappropriate sinus tachycardia",
"     </li>",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only the abrupt onset and termination of the arrhythmia aids clinically in differentiating SANRT from sinus tachycardia, which is not a paroxysmal condition but manifests a gradual increase and decrease in rate (",
"    <a class=\"graphic graphic_waveform graphicRef76364 \" href=\"mobipreview.htm?17/28/17862\">",
"     waveform 1",
"    </a>",
"    ). Other arrhythmias included in the differential diagnosis, however, typically have a P wave morphology that is different from normal, although the difference may be subtle. In addition, other reentrant tachycardias are usually, but not always, more rapid than SANRT (rate up to 240 beats per minute versus 100 to 150 beats per minute).",
"   </p>",
"   <p>",
"    A more in-depth discussion of the differential diagnosis of narrow QRS complex tachycardias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of SA nodal reentrant tachycardia require no specific therapy since the usual rates (100 to 150",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    rarely produce symptoms or hemodynamic compromise. However, persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic SANRT requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to acutely terminate SANRT should begin with vagal maneuvers. If vagal maneuvers are unsuccessful, intravenous adenosine can be administered for the acute termination of SANRT. Chronic suppressive therapy, when necessary, is usually with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    have been tried with some success. Catheter ablation of SANRT is generally the treatment of choice for chronic management of this arrhythmia given its efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autonomic maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the acute termination of symptomatic SANRT, we suggest carotid sinus massage or another vagal maneuver as the initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SA node has extensive autonomic innervation. As a result, carotid sinus massage and other vagal maneuvers (such as the Valsalva maneuver) generally terminate SA nodal reentrant arrhythmias",
"    <strong>",
"     abruptly",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/10,16,18\">",
"     10,16,18",
"    </a>",
"    ]. This is in contrast to the effect of vagal maneuvers on sinus tachycardia and reentrant intraatrial rhythms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to sinus tachycardia is characterized by",
"      <strong>",
"       gradual",
"      </strong>",
"      slowing and then gradual acceleration upon cessation of the maneuver.",
"     </li>",
"     <li>",
"      The atria are less well innervated than the sinus node. As a result, vagal stimulation has a variable and often negligible effect on reentrant intraatrial rhythms. Enhancement of vagal tone may, however, result in AV nodal blockade, which will result in a reduction in the ventricular rate without altering the atrial rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large studies of pharmacologic therapy in SA nodal reentrant tachycardia because of the rarity of the arrhythmia and its general lack of clinical consequence. Several drugs have been evaluated for both acute termination and chronic suppression of SANRT in small nonrandomized studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adenosine acutely terminated SANRT in six of six patients in a single-center cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      (two of two) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (four of four) effectively prevented induction of SANRT during electrophysiologic testing in a single-center cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers have not been extensively studied but failed to prevent induction of SANRT in two of two patients during electrophysiologic testing in a single-center cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ouabain, an analog of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , successfully prevented induction of SANRT during electrophysiologic testing in a single-center cohort. In addition, digoxin has been reported to successfully suppress recurrent SANRT for 18 months in an infant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456260\">",
"    <span class=\"h2\">",
"     Radiofrequency catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;SANRT is on occasion sufficiently symptomatic or persistent to warrant specific intervention. Increasing experience is being gained with radiofrequency ablation of a portion of the reentrant circuit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34166/abstract/13,17,21-24\">",
"     13,17,21-24",
"    </a>",
"    ]. Of approximately 45 patients in these reports, the arrhythmia recurred in only one patient who then underwent a second successful ablation. Evaluation in a larger number of patients with longer follow-up is required to more accurately determine the role of ablation in this disorder. However, we feel that catheter ablation should be considered as first-line therapy for symptomatic patients or in patients with persistent tachycardia who are at risk for or who have developed tachycardia-mediated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456202\">",
"    <span class=\"h2\">",
"     Our approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the limited available evidence, we take the following approach to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For acute termination of symptomatic SANRT that persists despite the use of vagal maneuvers, we suggest intravenous adenosine.",
"     </li>",
"     <li>",
"      For chronic suppression of recurrent SANRT, we suggest catheter ablation rather than pharmacologic therapy. This choice is based upon the high success rates of catheter ablation in conjunction with fewer potential long-term medication side effects.",
"     </li>",
"     <li>",
"      For chronic therapy of SANRT when ablation is not an option or has been unsuccessful in preventing recurrent SANRT, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      as the first choice, followed by the combination of both if SANRT recurs. If SANRT recurs despite the combination of verapamil and digoxin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13137704\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinoatrial nodal reentrant tachycardia (SANRT), also called \"sinus node reentry\" or \"sinus node reentrant tachycardia\", is a macroreentrant tachyarrhythmias involving the SA node",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perinodal tissue. (See",
"      <a class=\"local\" href=\"#H13137656\">",
"       'Definition and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SANRT occurs most commonly in adults and children who have structural heart disease and is estimated to be responsible for anywhere from 2 to 17 percent of supraventricular tachycardias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, the clinical manifestations and significance of SANRT are minimal. Most patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. (See",
"      <a class=\"local\" href=\"#H2771727\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SANRT should be considered in the presence of a regular but rapid pulse and heartbeat on physical examination. The electrocardiogram (ECG) will show P waves with a rate between 100 and 150 beats per minute. Given that the P waves are virtually identical to those observed in sinus rhythm, in most cases the diagnosis cannot be confirmed without invasive electrophysiologic studies. (See",
"      <a class=\"local\" href=\"#H13137664\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block). Only the abrupt onset and termination of the arrhythmia aids clinically in differentiating SANRT from sinus tachycardia, which is not a paroxysmal condition but manifests a gradual increase and decrease in rate. (See",
"      <a class=\"local\" href=\"#H13137688\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While SANRT is most often transient and asymptomatic, persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptomatic SANRT requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy. We take the following approach to treatment (see",
"      <a class=\"local\" href=\"#H2456202\">",
"       'Our approach to treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For acute termination of symptomatic SANRT that persists despite the use of vagal maneuvers, we suggest intravenous adenosine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For chronic suppression of recurrent SANRT, we suggest catheter ablation rather than pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This choice is based upon the high success rates of catheter ablation in conjunction with fewer potential long-term medication side effects.",
"     </li>",
"     <li>",
"      For chronic therapy of SANRT when ablation is not an option or has been unsuccessful in preventing recurrent SANRT, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      as the first choice (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), followed by the combination of both if SANRT recurs. If SANRT recurs despite the combination of verapamil and digoxin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is another option.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/1\">",
"      Saoudi N, Cos&iacute;o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.",
"     </a>",
"    </li>",
"    <li>",
"     Kirchhoff CJ, Bonke FI, Allessie MA. Sinus node reentry: Fact or fiction?. In: Cardiac Arrhythmias: Where to Go from Here?, Brugade P, Wellens HJ (Eds), Martinus Nijhoff, The Hague 1987. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/3\">",
"      Allessie MA, Bonke FI. Direct demonstration of sinus node reentry in the rabbit heart. Circ Res 1979; 44:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/4\">",
"      Childers RW, Arnsdorf MF, De la Fuente DJ, et al. Sinus nodal echoes. Clinical case report and canine studies. Am J Cardiol 1973; 31:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/5\">",
"      Paulay KL, Varghese PJ, Damato AN. Sinus node reentry. An in vivo demonstration in the dog. Circ Res 1973; 32:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/6\">",
"      Strauss HC, Bigger JT Jr. Electrophysiological properties of the rabbit sinoatrial perinodal fibers. Circ Res 1972; 31:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/7\">",
"      Bleeker WK, Mackaay AJ, Masson-P&eacute;vet M, et al. Functional and morphological organization of the rabbit sinus node. Circ Res 1980; 46:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/8\">",
"      Jalife J. Mutual entrainment and electrical coupling as mechanisms for synchronous firing of rabbit sino-atrial pace-maker cells. J Physiol 1984; 356:221.",
"     </a>",
"    </li>",
"    <li>",
"     Jalife J. Synchronization of pacemaker cells in the sinus node. In: Atrial Arrhythmias: Current Concepts and Management, Touboul P, Waldo AL (Eds), Mosby Year Book, St. Louis 1990. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/10\">",
"      Coss&uacute; SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis 1998; 41:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/11\">",
"      Narula OS. Sinus node re-entry: a mechanism for supraventricular tachycardia. Circulation 1974; 50:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/12\">",
"      Pahlajani DB, Miller RA, Serratto M. Sinus node re-entry and sinus node tachycardia. Am Heart J 1975; 90:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/13\">",
"      Gomes JA, Mehta D, Langan MN. Sinus node reentrant tachycardia. Pacing Clin Electrophysiol 1995; 18:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/14\">",
"      Garson A Jr, Gillette PC. Electrophysiologic studies of supraventricular tachycardia in children. I. Clinical-electrophysiologic correlations. Am Heart J 1981; 102:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/15\">",
"      Glaufox AD, Numan M, Knick BJ, et al. Sinoatrial node reentrant tachycardia in infants with congenital heart disease, Am J Cardiol 2001; 88:1054.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Supraventricular Tachycardias. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations, 4th, Lippincott, Williams, and Wilkins, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/17\">",
"      Kay GN, Chong F, Epstein AE, et al. Radiofrequency ablation for treatment of primary atrial tachycardias. J Am Coll Cardiol 1993; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/18\">",
"      Gomes JA, Hariman RJ, Kang PS, Chowdry IH. Sustained symptomatic sinus node reentrant tachycardia: incidence, clinical significance, electrophysiologic observations and the effects of antiarrhythmic agents. J Am Coll Cardiol 1985; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/19\">",
"      Engelstein ED, Lippman N, Stein KM, Lerman BB. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation 1994; 89:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/20\">",
"      Ozer S, Schaffer M. Sinus node reentrant tachycardia in a neonate. Pacing Clin Electrophysiol 2001; 24:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/21\">",
"      Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994; 89:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/22\">",
"      Sanders WE Jr, Sorrentino RA, Greenfield RA, et al. Catheter ablation of sinoatrial node reentrant tachycardia. J Am Coll Cardiol 1994; 23:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/23\">",
"      Ivanov MY, Evdokimov VP, Vlasenco VV. Predictors of successful radiofrequency catheter ablation of sinoatrial tachycardia. Pacing Clin Electrophysiol 1998; 21:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34166/abstract/24\">",
"      Goya M, Iesaka Y, Takahashi A, et al. Radiofrequency catheter ablation for sinoatrial node reentrant tachycardia: electrophysiologic features of ablation sites. Jpn Circ J 1999; 63:177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 918 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34166=[""].join("\n");
var outline_f33_23_34166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13137704\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13137656\">",
"      DEFINITION AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2771727\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13137664\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2771806\">",
"      Electrocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Electrophysiologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13137688\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autonomic maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456260\">",
"      Radiofrequency catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456202\">",
"      Our approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13137704\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/918|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/33/39441\" title=\"figure 1\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/56/7052\" title=\"table 1\">",
"      Electrophysiology in SVTach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/918|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?17/28/17862\" title=\"waveform 1\">",
"      ECG SA nodal reentrant tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=related_link\">",
"      Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34167="Pioglitazone and glimepiride: Drug information";
var content_f33_23_34167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pioglitazone and glimepiride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/58/41893?source=see_link\">",
"    see \"Pioglitazone and glimepiride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3340525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Duetact&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3340529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Thiazolidinedione;",
"     </li>",
"     <li>",
"      Hypoglycemic Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3340558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral: Initial dose should be based on current dose of pioglitazone and/or sulfonylurea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients inadequately controlled on",
"     <b>",
"      glimepiride",
"     </b>",
"     alone: Initial dose: 30 mg/2 mg or 30 mg/4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients inadequately controlled on",
"     <b>",
"      pioglitazone",
"     </b>",
"     alone: Initial dose: 30 mg/2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with systolic dysfunction (eg, NYHA Class I and II): Initiate only after patient has been safely titrated to 30 mg of pioglitazone. Initial dose: 30 mg/2 mg or 30 mg/4 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     No exact dosing relationship exists between glimepiride and other sulfonlyureas. Dosing should be limited to less than or equal to the maximum initial dose of glimepiride (2 mg). When converting patients from other sulfonylureas with longer half-lives (eg, chlorpropamide) to glimepiride, observe patient carefully for 1-2 weeks due to overlapping hypoglycemic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment:",
"     </b>",
"     Dosage may be increased up to max dose and formulation strengths available; tablet should not be given more than once daily; see individual agents for frequency of adjustments. Dosage adjustments in patients with systolic dysfunction should be done carefully and patient monitored for symptoms of worsening heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum dose: Pioglitazone 45 mg/glimepiride 8 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3340559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Initial: Glimepiride 1 mg/day prior to initiating Duetact&trade;; dose titration and maintenance dosing should be conservative to avoid hypoglycemia. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3340560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;22 mL/minute: Initial dose should be 1 mg of glimepiride and dosage increments should be based on fasting blood glucose levels.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3340561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Do not initiate treatment with active liver disease or ALT &gt;2.5 times ULN. During treatment, if ALT levels elevate &gt;3 times ULN, the test should be repeated as soon as possible. If ALT levels remain &gt;3 times ULN or if the patient is jaundiced, Duetact&trade; should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3340566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 30/2: Pioglitazone 30 mg and glimepiride 2 mg; 30/4: Pioglitazone 30 mg and glimepiride 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duetact&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30 mg/2 mg: Pioglitazone 30 mg and glimepiride 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30 mg/4 mg: Pioglitazone 30 mg and glimepiride 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3340527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9350996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021925s007mg.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021925s007mg.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3340562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily with the first main meal of the day. To avoid hypoglycemia, patients without oral intake may need to have the dose held.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3340530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise in patients already treated with a thiazolidinedione and a sulfonylurea or who have inadequate control on either agent alone",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3340541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (13% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (12% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (4% to 6%), nausea (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Limb pain (4% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3340536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glimepiride, pioglitazone, or any component of the formulation; diabetic ketoacidosis (with or without coma); NYHA Class III/IV heart failure (initiation of therapy)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3340537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder cancer: Clinical trial data suggest an increased risk of bladder cancer in patients exposed to pioglitazone; risk may be increased with duration of use. Avoid use in patients with active bladder cancer and consider risks vs. benefits prior to initiating therapy in patients with a history of bladder cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Dose-related edema, including new-onset or exacerbation of existing edema, has been reported with pioglitazone; use with caution in patients with edema. Monitor for signs/symptoms of heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of bone fractures in females treated with pioglitazone;  majority of fractures occurred in the lower limb and  distal upper limb. Consider risk of fracture prior to initiation and during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure/cardiac effects:",
"     <b>",
"      [U.S. Boxed Warning]: Thiazolidinediones, including pioglitazone, may cause or exacerbate heart failure; closely monitor for signs and symptoms of heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases; if heart failure develops, treat accordingly and consider dose reduction or discontinuation. Not recommended for use in any patient with symptomatic heart failure; initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure.",
"     </b>",
"     If used in patients with NYHA class I or II (systolic) heart failure, initiate at lowest dosage and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: May decrease hemoglobin/hematocrit; effects may be related to increased plasma volume.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic failure, including fatalities, has been reported with pioglitazone use. Monitor for signs/symptoms of liver injury closely during therapy; discontinuation of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy and all diabetic patients should have regular eye exams.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Dose-related weight gain observed with pioglitazone use; mechanism unknown but likely associated with fluid retention and fat accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with anemia; may reduce hemoglobin and hematocrit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes, type 1: Mechanism of pioglitazone requires the presence of insulin; therefore, use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use pioglitazone with caution in patients with minor elevations in transaminases (AST or ALT); do not initiate in patients with active liver disease of ALT &gt;2.5 times the upper limit of normal at baseline. During therapy, if ALT &gt;3 times the upper limit of normal, reevaluate levels promptly and discontinue if elevation persists or if jaundice occurs at any time during use. Idiosyncratic hepatotoxicity has been reported with another thiazolidinedione agent (troglitazone); avoid use in patients who previously experienced jaundice during troglitazone therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal/anovulatory females: Use pioglitazone with caution in premenopausal, anovulatory women; may result in a resumption of ovulation, increasing the risk of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3340547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3340546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione). Management: Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregabalin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3340548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3340531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3340532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination; therefore, pioglitazone/glimepiride is classified as pregnancy category C.  See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3340534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3340535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Duetact Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2 mg (30): $392.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-4 mg (30): $392.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pioglitazone HCl-Glimepiride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2 mg (30): $334.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-4 mg (30): $334.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3340564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of heart failure; routine ophthalmic exams are recommended; patients reporting visual deterioration should have a prompt referral to an ophthalmologist and consideration should be given to discontinuing  therapy; signs/symptoms of bladder cancer (dysuria, macroscopic hematuria, dysuria, urinary urgency); hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , serum glucose; liver enzymes and renal function prior to initiation and periodically during treatment.  If the ALT is increased to &gt;2.5 times ULN, liver function testing should be performed more frequently until the levels return to normal or pretreatment values.",
"     <b>",
"      Note:",
"     </b>",
"     If ALT levels elevate &gt;3 times ULN, the test should be repeated as soon as possible. If ALT levels remain &gt;3 times ULN or if the patient is jaundiced, therapy should be discontinued. Also monitor hemoglobin A",
"     <sub>",
"      1C",
"     </sub>",
"     , serum glucose and signs and symptoms of heart failure. Routine ophthalmic exams recommended; patients reporting visual deterioration should have a prompt referral to an ophthalmologist and consideration should be given to discontinuing pioglitazone.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3340553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adride P (IN);",
"     </li>",
"     <li>",
"      Asenza Plus (PH);",
"     </li>",
"     <li>",
"      Pioglit G (IN);",
"     </li>",
"     <li>",
"      Tandemact (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Zoliget (PH);",
"     </li>",
"     <li>",
"      Zorep-1 (PE);",
"     </li>",
"     <li>",
"      Zorep-2 (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3340551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: A thiazolidinedione that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glimepiride: A sulfonylurea that stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3340554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lago RM, Singh PP, and Nesto RW, &ldquo;Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370 (9593):1129-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/17905165/pubmed\" id=\"17905165\" target=\"_blank\">",
"        17905165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Wolski K, Nicholls SJ, et al, &ldquo;Pioglitazone an Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(10):1180-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/17848652/pubmed\" id=\"17848652\" target=\"_blank\">",
"        17848652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simpson SH, Majumdar SR, Tsuyuki RT, et al, &ldquo;Dose-Response Relation between Sulfonylurea Drugs and Mortalility in Type 2 Diabetes Mellitus: A Population-Based Cohort Study,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2006, 174(2):169-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/16415461/pubmed\" id=\"16415461\" target=\"_blank\">",
"        16415461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, &ldquo;Thiazolidinedione Use and Bone Loss in Older Diabetic Adults,&rdquo;",
"      <i>",
"       J Clin Endocrin Metab",
"      </i>",
"      , 2006, 91(9):3349-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/16608888/pubmed\" id=\"16608888\" target=\"_blank\">",
"        16608888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      University Group Diabetes Program, &ldquo;A Study of the Effects of Hypoglycemia Agents of Vascular Complications in Patients with Adult-Onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated with Tolbutamide,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaturu S, Bryant B, Jain SK, &ldquo;Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(6):1574-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/23/34167/abstract-text/17363747/pubmed\" id=\"17363747\" target=\"_blank\">",
"        17363747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9477 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34167=[""].join("\n");
var outline_f33_23_34167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709213\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340529\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340558\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340559\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340560\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340561\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340566\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340527\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9350996\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340562\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340530\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174559\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340541\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340536\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340537\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340547\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340548\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340531\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340532\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340534\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340535\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370391\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340564\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340553\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539980\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340551\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340554\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/58/41893?source=related_link\">",
"      Pioglitazone and glimepiride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34168="Keratosis pilaris dark skin";
var content_f33_23_34168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68488%7EDERM%2F60786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68488%7EDERM%2F60786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratosis pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratosis pilaris. Multiple follicularly-based hyperpigmented papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratosis pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratosis pilaris. Multiple mildly erythematous follicularly-based papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34168=[""].join("\n");
var outline_f33_23_34168=null;
var title_f33_23_34169="Burn pain: Principles of pharmacologic and nonpharmacologic management";
var content_f33_23_34169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Burn pain: Principles of pharmacologic and nonpharmacologic management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Shelley Wiechman, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Sam R Sharar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34169/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/23/34169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10926413\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns can be extremely painful. Pain management, which includes pharmacologic and nonpharmacologic approaches, is a central component of the complex issues involved in treating patients with burns. Despite advances in burn care, inadequate burn pain management still exists during both the acute and rehabilitation phases of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/1\">",
"     1",
"    </a>",
"    ]. Burn pain is among the most common causes of distress during the first year after discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Burn pain management is based upon tradition, personal bias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    institutional preference rather than based upon scientific approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of pharmacologic and nonpharmacologic options for the management of burn pain is reviewed here. Emergency care and local management of burns and pain are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38695?source=see_link\">",
"     \"Paradigm-based treatment approaches for burn pain control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10927394\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF BURN PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;All burns are painful initially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/5\">",
"     5",
"    </a>",
"    ]. Burn pain varies greatly from patient to patient, shows substantial fluctuation over the hospitalization course, and can be unpredictable due to the complex interaction of anatomic, physiologic, psychosocial, and premorbid behavior issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/6\">",
"     6",
"    </a>",
"    ]. Burn patients typically report pain as being severe or excruciating, despite receiving opioid analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn pain also varies depending upon depth of burn (",
"    <a class=\"graphic graphic_figure graphicRef73309 \" href=\"mobipreview.htm?24/50/25381\">",
"     figure 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial partial thickness burns result in hyperalgesia and mild to moderate pain. They are the most painful burns immediately following the injury. These burns damage only the outer layers of the skin.",
"     </li>",
"     <li>",
"      Moderate partial thickness burns are associated with marked hyperalgesia, and produce moderate to severe pain. Burns at this depth injure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inflame sensory receptors in the dermis.",
"     </li>",
"     <li>",
"      Deep partial thickness to full thickness burns are typically characterized by an absence of pain. Hyperalgesia to cutaneous stimulation is uncommon. Acute pain is typically minimal, but can be variable, and is universally present with respect to the transition zone between burned and unburned skin. The dermis is completely destroyed, including its sensory and vascular structures. There is little to no response to sharp stimuli, yet patients complain of a deep aching pain related to the inflammatory response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11800749\">",
"    <span class=\"h1\">",
"     BURN PAIN ASSESSMENT TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain assessment tools must be practical, reliable, and valid, and must be able to assess three dimensions of pain: pain intensity, behavioral reactions, and physiologic reactions. A variety of pain measurement tools have been used with adult and pediatric burn patients. However, there are no randomized trials that have identified an optimal assessment technique for burn patients. The key is to choose an instrument and use it consistently. The most common tools used for adults and children with burn pain include verbal adjective scales, numeric written or visual analog scales, pain assessment in dementia scales, FACES, and FLACC (Face, Legs, Activity, Cry, Consolability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11800756\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more common tools for assessing post burn pain in adults are the adjective scales, which allow a patient to describe the severity of pain in words, such as &ldquo;none, mild, moderate, or severe&rdquo; or &ldquo;no pain, mild, discomforting, distressing, horrible, or excruciating pain&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef80858 \" href=\"mobipreview.htm?15/61/16348\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/11\">",
"     11",
"    </a>",
"    ]. An alternative to the verbal description of pain is the numeric scale, which allows a patient to describe the pain on a scale of increasing severity typically from 0 to 10 (",
"    <a class=\"graphic graphic_figure graphicRef72905 \" href=\"mobipreview.htm?6/8/6285\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/10\">",
"     10",
"    </a>",
"    ]. The numeric scale is administered to the patient verbally or written as a visual analog scale (",
"    <a class=\"graphic graphic_figure graphicRef62346 \" href=\"mobipreview.htm?41/46/42723\">",
"     figure 4",
"    </a>",
"    ). Pain assessment can be challenging in the burned and demented patient. The Pain Assessment in Advanced Dementia Scale, an observational scoring instrument, is a simple to administer valid and reliable instrument (",
"    <a class=\"graphic graphic_table graphicRef59509 \" href=\"mobipreview.htm?24/9/24732\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link&amp;anchor=H3#H3\">",
"     \"Pain control in the critically ill adult patient\", section on 'Assessment and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11800763\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of children's pain is much more complex than it is for adults, especially for preverbal children. Typical physiologic indicators, such as heart rate, respiratory rate, and blood pressure are unreliable in measuring a child&rsquo;s pain since all are affected by a variety of stressors related to the burn injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation and management of pain in children\", section on 'Assessment of pain severity and cognition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Behavior scales have been devised to measure pain by providing standardized instructions and guidelines for observing behaviors thought to be specific to pain. Facial expression may be the most consistent infant indicator of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/13\">",
"     13",
"    </a>",
"    ]. Observational scales have been developed that are multidimensional and include length of cry, facial expressions, and behavioral states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"     3",
"    </a>",
"    ]. These scales are easier to use and allow an observer to assess pain as either present or absent without further quantification. The FLACC (Faces Legs Activity Cry Consolability scale) is the most widely used observer rating scale in preverbal children (",
"    <a class=\"graphic graphic_table graphicRef81819 \" href=\"mobipreview.htm?7/25/7581\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple self-report pain scales can be used with preschool children. There is no evidence that any one of these scales is more reliable than the other, hence, it is best to select one that the evaluator prefers and it should be used consistently. When self-report scales are used in conjunction with observational scales, a practitioner may develop a better appreciation of the intensity of the child's response to burn pain and the effectiveness of pain management. The following are examples of pain scales that are commonly used with children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Wong-Baker FACES Pain Scale is designed for children three years and older (",
"      <a class=\"graphic graphic_figure graphicRef51021 \" href=\"mobipreview.htm?26/20/26944\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/9\">",
"       9",
"      </a>",
"      ]. This pain scale uses drawings of faces",
"      <sup>",
"      </sup>",
"      displaying varying degrees of pain and discomfort. Each face communicates a level of pain intensity and the child is asked to choose the face that most accurately describes their pain level.",
"     </li>",
"     <li>",
"      The OUCHER scale includes a picture scale for very young children and a numerical scale that can be used in children over five years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/15\">",
"       15",
"      </a>",
"      ]. There are different versions that can be used for children of various races, and an example is shown for a Caucasian boy (",
"      <a class=\"graphic graphic_figure graphicRef75312 \" href=\"mobipreview.htm?31/16/32000\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11800898\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents used to treat burn pain include opioid analgesics, nonopioid analgesics, anxiolytics, and anesthetics. The type of medication used is determined by the severity of pain, the anticipated duration of pain, and intravenous (IV) access. These medications have variable durations of action, particularly in burn patients, and should be titrated to meet the needs of the patient in each clinical setting.",
"   </p>",
"   <p>",
"    Pharmacologic techniques should provide near-constant plasma levels of analgesics through regularly scheduled administration of long-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ), or continuous IV opioid infusion (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) in patients unable to take oral medications. Regularly schedule benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) may have added value in patients with significant anxiety that contributes to their pain experience.",
"   </p>",
"   <p>",
"    A severe burn injury results in physiologic changes that may alter the pharmacokinetic and pharmacodynamic response to drugs in inconsistent ways, hence deviation from the usual doses may be necessary to avoid toxicity or decreased efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/16\">",
"     16",
"    </a>",
"    ]. The tables linked to this topic provide dosages of opioids and nonopioid analgesias as recommended for patients without serious pathophysiologic and metabolic changes without altered drug clearance. These dosages serve as a reference point for administering pharmacologic agents to burned patients. Medications may be more potent and have a prolonged effect in the burn patient. Monitoring of the airway, breathing, and circulation is necessary, particularly when intravenous drugs are administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11801092\">",
"    <span class=\"h2\">",
"     Opioid analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid analgesics, the most common type of medication used for acute pain relief, are potent and provide a dose dependent degree of sedation important during burn wound care procedures (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"mobipreview.htm?19/40/20111\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76614 \" href=\"mobipreview.htm?29/50/30508\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"     3",
"    </a>",
"    ]. Burn pain should be treated aggressively and there is no clear evidence that the use of opioids during acute burn pain management increases the likelihood of opioid dependency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/17\">",
"     17",
"    </a>",
"    ]. A review of intravenous opioid analgesia for adults and children is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link&amp;anchor=H6#H6\">",
"     \"Pain control in the critically ill adult patient\", section on 'Intravenous analgesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H14#H14\">",
"     \"Procedural sedation in adults\", section on 'Medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and management of pain in children\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids can be administered intravenously or orally, depending on IV access, gastrointestinal function, and the patient&rsquo;s ability to cooperate. For severe pain, the optimal route of administration is IV, which provides faster pain relief and can be titrated to meet the individual needs of the patient.",
"    <br/>",
"    <br/>",
"    Patient-controlled analgesia (PCA) with IV opioids offers the burn patient a safe and efficient method of achieving more flexible analgesia, provided the patient is alert and competent to use the device (",
"    <a class=\"graphic graphic_table graphicRef51791 \" href=\"mobipreview.htm?9/50/10029\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of postoperative pain\", section on 'Patient controlled analgesia'",
"    </a>",
"    .) Studies comparing PCA opioid use to other routes of administration in the burn population have shown positive, but limited benefits of PCA.",
"    <br/>",
"    <br/>",
"    Oral or gastrointestinal administration of opioids via an enteral tube provides potent pain relief with rapid onset and short duration of action, and requires minimal monitoring. Oral transmucosal administration is particularly helpful for performing burn dressing changes in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intramuscular opioid administration is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for use in burn patients. The injections are painful, they need to be repeated frequently, and the absorption is variable due to compartmental fluid shifts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Fluid resuscitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergency care of moderate and severe thermal burns in children\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11801099\">",
"    <span class=\"h2\">",
"     Nonopioid analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonopioid analgesics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , provide short-term effective analgesia and sedation that may be helpful for limited burn debridement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dressing changes in adults and children. Dexmedetomidine provides sedation, anxiolysis, and analgesia for burned children, with less respiratory depression than other sedatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In case study reports, ketamine used in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    has been effective in providing analgesia and sedation in children with severe burn pain, particularly during dressing changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H20#H20\">",
"     \"Procedural sedation in adults\", section on 'Ketamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H3220179#H3220179\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Dexmedetomidine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H7977200#H7977200\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25082?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nonopioid analgesics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal anti-inflammatory drugs (NSAIDS), provide mild analgesia and are best suited to treat minor burn pain in the outpatient setting (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"mobipreview.htm?23/54/24431\">",
"     table 6",
"    </a>",
"    ). Oral NSAIDs and acetaminophen exhibit a ceiling effect in their dose-response relationship, rendering them unsuitable for the treatment of severe burn pain. There are no high quality data from randomized trials that have determined the optimal nonopioid analgesic for burn patients. The mechanism of action and therapeutic use of NSAIDS is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11801106\">",
"    <span class=\"h2\">",
"     Anxiolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is a common consequence of burns, due to the need for aggressive surgical treatment and debridement of the wounds, and the persistent and repetitive qualities of background and procedural burn pain. The recognition that anxiety can exacerbate acute pain has led to the common practice of using anxiolytic drugs in combination with opioid analgesics, a practice that has become more widespread in burn centers in the past two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This practice is particularly useful in premedicating patients for wound care, due to the anticipatory anxiety experienced by these patients prior to and during such procedures.",
"   </p>",
"   <p>",
"    Benzodiazepine therapy improved postprocedure pain scores in burn patients (",
"    <a class=\"graphic graphic_table graphicRef65653 \" href=\"mobipreview.htm?39/16/40205\">",
"     table 7",
"    </a>",
"    ). A trial that randomly assigned 79 burn patients to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    1 mg or placebo in addition to their standard opioid analgesics found no difference between groups in pain score, except in patients with high baseline pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/27\">",
"     27",
"    </a>",
"    ]. In high baseline pain patients, lorazepam significantly reduced VAS pain score ratings (54.3 versus 69.1). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antipsychotic medications are also an option for management of anxiety and agitation associated with burn pain and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation antipsychotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) are used adjunctively for treatment or prevention of hyperactive delirium and agitation in critically ill patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25082?source=see_link&amp;anchor=H11#H11\">",
"       \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\", section on 'Neuroleptics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Second generation antipsychotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ) are increasingly used for treating various anxiety disorders and may be useful in combination with a benzodiazepine for managing anxiety and improving sleep in burn patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11801113\">",
"    <span class=\"h2\">",
"     Anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, neuraxial, targeted nonneuraxial, and regional anesthetics are useful in managing burn pain in various clinical settings. The specific types and administration of anesthesia are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38726099\">",
"    <span class=\"h3\">",
"     General or deep sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general anesthetic or deep sedation provides relief of relatively brief, intense pain that would be experienced during a procedure, such as skin grafting, extensive wound debridement, or dressing changes that occur outside of the operating room. While the risks of complications following a general anesthetic are typically low in healthy individuals, burn patients have metabolic, physiologic, and thermoregulatory abnormalities as well as possible inhalation injuries that are associated with increased risk of complications of perioperative hypothermia, hypoxemia, and abnormal responses to both depolarizing and non-depolarizing muscle relaxants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    is an anesthetic agent that can be safely administered and provides effective analgesia without loss of consciousness (ie, moderate sedation) for moderately painful procedures. It can be used for the treatment of burn pain, typically as a 50 percent mixture in 50 percent oxygen, and self-administered by an awake, cooperative, and spontaneously breathing patient via a mouthpiece or mask [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Full anesthetic care capabilities have been extended outside the operating room into specialized, high volume burn center intensive care units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Drugs, such as intravenously administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    and inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    , with rapid onset and short duration of action, rapid recovery, and few side effects have facilitated burn care and pain management in the patient&rsquo;s hospital bed without transporting the patient to the operating room. The occasional provision of brief, dense",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    (eg, general anesthesia or deep sedation) should be administered in a comprehensively monitored setting by medical professionals specifically trained to provide the service. When administered in a controlled environment, a general anesthesia or deep sedation is safe and efficient, both in terms of allowing wound care (eg, debridement of facial burns in children) to proceed rapidly, and in terms of cost-effective use of the operating room only for true surgical burn care procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38726107\">",
"    <span class=\"h3\">",
"     Regional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional anesthesia is achieved by injecting a local anesthetic agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) around a nerve to block the sensory stimulation from that area innervated by the nerve. A regional anesthesia is particularly useful for procedures and burn pain relief involving the extremities. The most common nerve groups accessible for a nerve block include the brachial plexus (interscalene block, infraclavicular block, axillary block), the sciatic nerve, and the femoral nerve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38726115\">",
"    <span class=\"h4\">",
"     Neuraxial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial anesthesia is the administration of an anesthetic agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opioid analgesics via a spinal or epidural catheter with the goal of providing background, procedural, and postoperative pain relief. This procedure has only been anecdotally used in burn patients but theoretically has the advantage of providing an autonomic sympathectomy and peripheral dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/34\">",
"     34",
"    </a>",
"    ]. A major drawback to the use of neuraxial anesthesia is the potential colonization of the indwelling catheter, particularly if inserted through burned skin, and the associated risks of meningitis and epidural abscess formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38726220\">",
"    <span class=\"h4\">",
"     Targeted non-neuraxial blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to neuraxial anesthesia, targeted non-neuraxial regional blockade is relatively easy to perform and carries minimal risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. An example of a non-neuraxial nerve block is the fascia iliaca compartment blockade (FICB), which can be used for lower extremity analgesia following skin graft harvesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11800906\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic treatments should be complementary to pharmacologic approaches when treating pain and anxiety in the burn patient. Empirical evidence for the efficacy of nonpharmacologic treatments has been reported with burn pain, particularly when used as an adjunct to opioid analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of nonpharmacologic approaches are available. In choosing the most effective approach, the team should be guided by the manner in which the patient typically responded to prior stressful medical procedures, if possible. Such responses lie on a continuum ranging from giving up control to the health care professional and desiring little information, to seeking out as much information as possible and actively participating in care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/38\">",
"     38",
"    </a>",
"    ]. The following examples illustrate the types of coping styles to burn and procedural pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance &mdash; Those burn patients who wish to give up control to the health care professional have a tendency toward cognitive avoidance, or an avoidance style of coping mechanism. They will likely use various types of distraction techniques to avoid the painful stimuli.",
"     </li>",
"     <li>",
"      Approach &mdash; Those burn patients who seek out information about the procedure and attempt to participate and not relinquish control have an &ldquo;approach&rdquo; style of coping mechanism. These patients often find distraction techniques distressing as trying to ignore a procedure may serve to relinquish too much control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that both coping styles can be adaptive and it is best for the burn care team to support an individual&rsquo;s coping style rather than try to change the natural response. Patients may also change their coping style depending on the procedure. As an example, a patient may find it is easier to use distraction techniques for short procedures such as receiving injections, whereas they are more comfortable attending to details of their long wound care sessions and participating when possible. Patients may also change their coping style as they become more familiar and comfortable with the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133671\">",
"    <span class=\"h2\">",
"     Avoidance techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance interventions are designed to psychologically distract or distance the patient from the pain. The Multiple Resource Theory of Attention suggests that diverting attention towards a nonpainful stimulus may lessen the intensity of perceived pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/39\">",
"     39",
"    </a>",
"    ]. The four interventions in the avoidance category include distraction, guided imagery, hypnotic analgesia, and virtual reality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"     3",
"    </a>",
"    ]. The nonpharmacological techniques are described in order of those more appropriate for avoidance coping styles towards those more appropriate for the approach coping styles. However, randomized trials have not been performed to determine the optimal diversion approach as an adjunct for managing pain in burn patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133254\">",
"    <span class=\"h3\">",
"     Distraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distraction is the most common intervention activated by patients or the provider as an adjunct for pain management in burned children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/40\">",
"     40",
"    </a>",
"    ].The types of distraction techniques available to reduce burn pain are limited only by the creativity of patients and health care professionals. Common distraction techniques used with children include bubble blowing, singing songs, reading a story, and counting. Generating distraction strategies for adults may require a bit more creativity, and include engaging in enjoyable conversation during the procedure, listening to music, or playing a video game [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133268\">",
"    <span class=\"h3\">",
"     Guided imagery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imagery is an integrative therapy that incorporates imagined pictures, sounds, or sensations for specific therapeutic goals, such as the reduction of burn pain. While the patient is engaged in the imagery scene, less attention is available for the painful stimuli. It is the patient that selects the imagery. A related discussion on imagery and pain control in cancer patients can be found using the following link. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713432#H44713432\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Imagery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients using imagery simply create or recreate an image in their mind, presumably one that they find pleasant and engaging. Prior to a painful procedure, we often have the patient elicit a &ldquo;safe&rdquo; or &ldquo;favorite&rdquo; place to go. This can be a place where they have been before (eg, a favorite vacation spot) or simply a place that they imagine to be relaxing and safe. The clinician then simply cues the patient with the details that they have provided and we encourage them to imagine this place during their subsequent wound care.",
"   </p>",
"   <p>",
"    Limited evidence suggests that guided imagery is effective in reducing the sensory and emotional components of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/42\">",
"     42",
"    </a>",
"    ]. The Agency for Health Care Policy and Research advocates the use of imagery for reduction of pain intensity and distress for cancer pain and for the management of mild to severe acute pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133302\">",
"    <span class=\"h3\">",
"     Hypnotic analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnosis is an altered state of consciousness characterized by an increased receptivity to suggestion, ability to alter perceptions and sensations, and an increased capacity for dissociation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/44\">",
"     44",
"    </a>",
"    ]. It is believed that the dramatic shift in consciousness that occurs with hypnosis is the cornerstone of an individual&rsquo;s ability to change their awareness of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/45\">",
"     45",
"    </a>",
"    ]. Hypnotic analgesia should only be used by trained clinicians who can assess the risks and benefits of this powerful technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hypnosis involves much more than just avoidance or distraction, the end result is often similar, the patient&rsquo;s focus is diverted from the pain or painful procedure. Several features make hypnotic analgesia a unique method of pain control that differs markedly from imagery or relaxation. Hypnosis may or may not lead to relaxation depending on the nature of the suggestions. In turn, it is not necessary for a patient to be relaxed or even in a deep hypnotic state in order for suggestions to be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/47\">",
"     47",
"    </a>",
"    ]. A related discussion on hypnotic analgesia and pain control in cancer patients can be found using the following link. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713439#H44713439\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Hypnotic analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypnosis involves several stages, including building clinician-patient rapport, enhancing relaxation through deep breathing, suggestions for deepening the hypnotic state, and narrowing their attention, providing posthypnotic suggestions, and alerting stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/48\">",
"     48",
"    </a>",
"    ]. Burn patients are good candidates for hypnotic analgesia because [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intense nature and severity of burn pain motivates patients to engage in hypnosis.",
"     </li>",
"     <li>",
"      The behavioral regression that often occurs after a traumatic injury makes patients more willing to be taken care of by others.",
"     </li>",
"     <li>",
"      Patients with burn injuries often experience a dissociative response as a means of coping that may moderate hypnotizability.",
"     </li>",
"     <li>",
"      Procedures, which cause the most intense pain, can be scheduled and thus allow hypnosis to be performed in advance of the painful stimulus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown the positive effect of hypnosis when used in conjunction with prescribed analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/49,52-55\">",
"     49,52-55",
"    </a>",
"    ]. Patients with higher baseline pain levels have a greater decrease in pain after hypnosis than patients with lower baseline pain levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/49\">",
"     49",
"    </a>",
"    ]. However, these studies are limited by methodological differences, lack of uniform assessment of hypnotizability and severity of pain, and small series of burn patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133707\">",
"    <span class=\"h3\">",
"     Virtual reality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtual reality diverts attention away from the painful sensations by immersing patients in a computer generated environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3,56\">",
"     3,56",
"    </a>",
"    ]. Burn patients can interact with the computer while painful procedures, such as dressing changes, are performed. Observational and small controlled studies indicate that virtual reality is effective in reducing pain and may have utility when used in conjunction with hypnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104704109\">",
"    <span class=\"h2\">",
"     Approach technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used approach technique is information provision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H810810\">",
"    <span class=\"h3\">",
"     Information provision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information provision, a technique that actively involves patient input, is an essential element of managing burn pain by providing treatment information in a timely and targeted manner. Information provision assists patient&rsquo;s understanding of the issues, alternatives, and solutions. This process provides information on how their input will affect the end result, and sharing information can build trust and mutual understanding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133699\">",
"    <span class=\"h2\">",
"     Relaxation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation techniques are used to lower arousal, including unnecessary muscle tension that can increase pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3,61\">",
"     3,61",
"    </a>",
"    ]. The techniques include deep breathing exercises, progressive muscle relaxation exercises, and cognitive behavioral techniques. There are no randomized trials to determine the optimal relaxation technique to be used as an adjunct for burn pain management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133830\">",
"    <span class=\"h3\">",
"     Deep breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep breathing, or diaphragmatic breathing, is one of the least time consuming techniques to employ and easiest for adults and children to learn. When a person becomes anxious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    experiences pain, breathing can become shallow and irregular due to the increased muscle tension in our chest wall. Such shallow breathing, known as thoracic breathing, leads to an increase in muscle tension and subsequent heightened pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deep breathing techniques allow patients to become aware of shallow irregular breathing and leads to relaxation that may alleviate some pain. Children can be taught bubble blowing or blowing on a pinwheel to encourage deep breathing. Adults can be taught to place a hand on their stomach and to take a breath deep enough that it passes through their chest and fills their stomach (shallow breathing is more in the chest and will not cause as much hand movement on the stomach). Their hand should rise and fall with the stomach. Exhalation is the most important part of deep breathing exercises and should not be rushed. Diaphragmatic breathing is central to all forms of relaxation and is simple and time efficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133838\">",
"    <span class=\"h3\">",
"     Progressive muscle relaxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle tension increases as patients experience stress and pain, hence the focused effort on relaxing and tensing muscles in a controlled manner diverts the attention away from the pain. Progressive muscle relaxation is a technique used to reduce anxiety associated with painful stimuli, such as burn dressing changes, by alternately tensing then relaxing muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/62\">",
"     62",
"    </a>",
"    ]. Muscles are sequentially tensed (10 seconds) and relaxed (20 seconds) through various parts of the body and can be performed during dressing changes. Observational studies suggest that progressive muscle relaxation can decrease recuperation time for hospitalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/62\">",
"     62",
"    </a>",
"    ]. If a person is unable to actively tense a muscle group due to pain or injury, he or she can still imagine each muscle becoming progressively &ldquo;warm, heavy, and relaxed&rdquo; or listen to a tape, a process known as autogenic training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136378\">",
"    <span class=\"h2\">",
"     Cognitive behavioral techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is used to treat multiple conditions by changing thoughts and behaviors. For treatment of burn patients, CBT includes diversion, information provision, coping skills, and relaxation techniques to modify the patient&rsquo;s thought process about the painful experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expectations of a bad outcome, such as intense pain, are associated with higher levels of perceived pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/63\">",
"     63",
"    </a>",
"    ]. CBT can be used adjunctively to manage these expectations and associated pain in the following manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34169/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognize that the procedure will cause pain (anticipatory pain or distress).",
"     </li>",
"     <li>",
"      Stop the thought that the procedure will cause pain by active efforts to block the thought process.",
"     </li>",
"     <li>",
"      Distract from the pain by diverting attention to another thought.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13088947\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The control of burn pain is a challenge that demands creativity and continued staff training on pain assessment, traditional pharmacologic analgesic approaches, and adjunctive nonpharmacologic techniques. Pharmacologic analgesics should be administered by trained and experienced staff in monitored conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain, which is present at least initially in all burn patients, varies greatly from patient to patient, shows substantial fluctuation over the hospitalization course, and can be unpredictable due to the complex interaction of anatomic, physiologic, psychosocial, and premorbid behavior. (See",
"      <a class=\"local\" href=\"#H10927394\">",
"       'Characteristics of burn pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain assessment instruments use visual",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      numeric scales to assess pain intensity, behavioral reactions, and physiologic reactions. There is no one optimal assessment technique for burn patients. The key is to choose an instrument and use it consistently. (See",
"      <a class=\"local\" href=\"#H11800749\">",
"       'Burn pain assessment techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic agents used to treat burn pain include opioid analgesics, nonopioid analgesics, anxiolytics, and anesthetics. The type of medication used is determined by the severity of pain, the anticipated duration of pain, and intravenous (IV) access. (See",
"      <a class=\"local\" href=\"#H11800898\">",
"       'Pharmacologic treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioid analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ), the most common type of medication used for acute pain relief, are potent and provide a dose dependent degree of sedation important during burn wound care procedures. (See",
"      <a class=\"local\" href=\"#H11801092\">",
"       'Opioid analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonopioid analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      , NSAIDs), provide short-term effective analgesia and sedation that may be helpful for limited burn debridement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dressing changes in adults and children. (See",
"      <a class=\"local\" href=\"#H11801099\">",
"       'Nonopioid analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anxiolytic drugs (eg, benzodiazepines) are useful in premedicating patients for wound care, due to the anticipatory anxiety experienced by these patients prior to and during such procedures. (See",
"      <a class=\"local\" href=\"#H11801106\">",
"       'Anxiolytics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic treatments should be adjunctive to pharmacologic approaches when treating pain and anxiety in the burn patient. These approaches include cognitive distraction, information provision, relaxation, coping skills, and cognitive behavioral techniques. (See",
"      <a class=\"local\" href=\"#H11800906\">",
"       'Nonpharmacologic treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/1\">",
"      Ptacek JT, Patterson DR, Montgomery BK, Heimbach DM. Pain, coping, and adjustment in patients with burns: preliminary findings from a prospective study. J Pain Symptom Manage 1995; 10:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/2\">",
"      Askay SW, Stricklin M, Carrougher GJ, et al. Using QMethodology to identify reasons for distress in burn survivors postdischarge. J Burn Care Res 2009; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/3\">",
"      Wiechman Askay S, Patterson DR, Sharar SR, et al. Pain management in patients with burn injuries. Int Rev Psychiatry 2009; 21:522.",
"     </a>",
"    </li>",
"    <li>",
"     Burn Pain: A Unique Challenge. Pain Clinical Updates. International Association for the Study of Pain. Vol IX, Issue 1. March 2001. www.iasp-pain.org.",
"    </li>",
"    <li>",
"     Meyer WJ, III, Patterson DR, et al. Chapter 64. Management of pain and other discomforts in burned patients. In: Total Burn Care, 3rd, Herndon DN. (Ed), Saunders Elsevier, Philadelphia 2007. p.797.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/6\">",
"      Choini&egrave;re M, Melzack R, Rondeau J, et al. The pain of burns: characteristics and correlates. J Trauma 1989; 29:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/7\">",
"      Perry S, Inturrisi C. Analgesia and morphine disposition in burn patie. J Burn Care Rehabil 1983; 4:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/8\">",
"      Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs 1997; 23:293.",
"     </a>",
"    </li>",
"    <li>",
"     Wong DL, Hockenberry-Eaton M, Wilson D, et al. Wong's Essentials of Pediatric Nursing, 6th edition, St. Louis 2001. p.1301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/10\">",
"      Wibbenmeyer L, Sevier A, Liao J, et al. Evaluation of the usefulness of two established pain assessment tools in a burn population. J Burn Care Res 2011; 32:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/11\">",
"      Gaston-Johansson F, Albert M, Fagan E, Zimmerman L. Similarities in pain descriptions of four different ethnic-culture groups. J Pain Symptom Manage 1990; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/12\">",
"      Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/13\">",
"      Johnston CC, Strada ME. Acute pain response in infants: a multidimensional description. Pain 1986; 24:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/14\">",
"      Stoddard FJ, Sheridan RL, Saxe GN, et al. Treatment of pain in acutely burned children. J Burn Care Rehabil 2002; 23:135.",
"     </a>",
"    </li>",
"    <li>",
"     Beyer JE, Villarruel AM, Denyes MJ. The Oucher! User&rsquo;s manual and technical report, January 2010. www.oucher.org/index.html (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     Woodson LC, Sherwood ER, Aarsland A, et al. Chapter 14: Anesthesia for burned patients. In: Total Burn Care, 3rd, Herndon DN. (Ed), Saunders Elsevier, Philadelphia  p.196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/17\">",
"      Abdi S, Zhou Y. Management of pain after burn injury. Curr Opin Anaesthesiol 2002; 15:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/18\">",
"      Rovers J, Knighton J, Neligan P, Peters W. Patient-controlled analgesia in burn patients: a critical review of the literature and case report. Hosp Pharm 1994; 29:106, 108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/19\">",
"      Sharar SR, Bratton SL, Carrougher GJ, et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil 1998; 19:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/20\">",
"      Sharar SR, Carrougher GJ, Selzer K, et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2002; 23:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/21\">",
"      Lin H, Faraklas I, Sampson C, et al. Use of dexmedetomidine for sedation in critically ill mechanically ventilated pediatric burn patients. J Burn Care Res 2011; 32:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/22\">",
"      Walker J, Maccallum M, Fischer C, et al. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res 2006; 27:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/23\">",
"      Kariya N, Shindoh M, Nishi S, et al. Oral clonidine for sedation and analgesia in a burn patient. J Clin Anesth 1998; 10:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/24\">",
"      Lyons B, Casey W, Doherty P, et al. Pain relief with low-dose intravenous clonidine in a child with severe burns. Intensive Care Med 1996; 22:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/25\">",
"      Martin-Herz SP, Patterson DR, Honari S, et al. Pediatric pain control practices of North American Burn Centers. J Burn Care Rehabil 2003; 24:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/26\">",
"      Perry S, Heidrich G. Management of pain during debridement: a survey of U.S. burn units. Pain 1982; 13:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/27\">",
"      Patterson DR, Ptacek JT, Carrougher GJ, Sharar SR. Lorazepam as an adjunct to opioid analgesics in the treatment of burn pain. Pain 1997; 72:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/28\">",
"      Vulink NC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011; 21:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/29\">",
"      MacLennan N, Heimbach DM, Cullen BF. Anesthesia for major thermal injury. Anesthesiology 1998; 89:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/30\">",
"      Filkins SA, Cosgrav P, Marvin JA. Self-administered anesthesia:  A method of pain control. J Burn Care Rehabil 1981; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/31\">",
"      Baskett PJ, Hyland J, Deane M, Wray G. Analgesia for burns dressing in children. A dose-finding study for phenoperidine and droperidol with and without 50 per cent nitrous oxide and oxygen. Br J Anaesth 1969; 41:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/32\">",
"      Dimick P, Helvig E, Heimbach D, et al. Anesthesia-assisted procedures in a burn intensive care unit procedure room: benefits and complications. J Burn Care Rehabil 1993; 14:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/33\">",
"      Powers PS, Cruse CW, Daniels S, Stevens BA. Safety and efficacy of debridement under anesthesia in patients with burns. J Burn Care Rehabil 1993; 14:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/34\">",
"      Punja K, Graham M, Cartotto R. Continuous infusion of epidural morphine in frostbite. J Burn Care Rehabil 1998; 19:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/35\">",
"      Still JM, Abramson R, Law EJ. Development of an epidural abscess following staphylococcal septicemia in an acutely burned patient: case report. J Trauma 1995; 38:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/36\">",
"      Cuignet O, Pirson J, Boughrouph J, Duville D. The efficacy of continuous fascia iliaca compartment block for pain management in burn patients undergoing skin grafting procedures. Anesth Analg 2004; 98:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/37\">",
"      Cuignet O, Mbuyamba J, Pirson J. The long-term analgesic efficacy of a single-shot fascia iliaca compartment block in burn patients undergoing skin-grafting procedures. J Burn Care Rehabil 2005; 26:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/38\">",
"      Martin-Herz SP, Thurber CA, Patterson DR. Psychological principles of burn wound pain in children. II: Treatment applications. J Burn Care Rehabil 2000; 21:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/39\">",
"      Wickens CD, Helleberg J, Xu X. Pilot maneuver choice and workload in free flight. Hum Factors 2002; 44:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/40\">",
"      Hanson MD, Gauld M, Wathen CN, Macmillan HL. Nonpharmacological interventions for acute wound care distress in pediatric patients with burn injury: a systematic review. J Burn Care Res 2008; 29:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/41\">",
"      Landolt MA, Marti D, Widmer J, Meuli M. Does cartoon movie distraction decrease burned children's pain behavior? J Burn Care Rehabil 2002; 23:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/42\">",
"      Eller LS. Guided imagery interventions for symptom management. Annu Rev Nurs Res 1999; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/43\">",
"      Acute pain management: operative or medical procedures and trauma, Part 2. Agency for Health Care Policy and Research. Clin Pharm 1992; 11:391.",
"     </a>",
"    </li>",
"    <li>",
"     Patterson DR. Clinical hypnosis for pain control. American Psychological Association: Washington, DC, US. 2010. page 37.doi: 10.1037/12128-002. psycnet.apa.org/books/12128/ (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     Barber J. A brief introduction to hypnotic analgesia. In: Hypnosis and Suggestion in the Treatment of Pain, Barber J (Ed), WW Norton &amp; Company, New York 1996. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/46\">",
"      Barber J. Rapid induction analgesia: a clinical report. Am J Clin Hypn 1977; 19:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/47\">",
"      Wark DM. Alert hypnosis: a review and case report. Am J Clin Hypn 2006; 48:291.",
"     </a>",
"    </li>",
"    <li>",
"     Patterson DR. Burn Pain. In: Hypnosis and Suggestion in the Treatment of Pain, Barber J (Ed), WW Norton &amp; Company, New York 1996. p.267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/49\">",
"      Patterson DR, Everett JJ, Burns GL, Marvin JA. Hypnosis for the treatment of burn pain. J Consult Clin Psychol 1992; 60:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/50\">",
"      Patterson DR, Adcock RJ, Bombardier CH. Factors predicting hypnotic analgesia in clinical burn pain. Int J Clin Exp Hypn 1997; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/51\">",
"      Patterson DR, Ptacek JT. Baseline pain as a moderator of hypnotic analgesia for burn injury treatment. J Consult Clin Psychol 1997; 65:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/52\">",
"      Montgomery GH, DuHamel KN, Redd WH. A meta-analysis of hypnotically induced analgesia: how effective is hypnosis? Int J Clin Exp Hypn 2000; 48:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/53\">",
"      Patterson DR, Jensen MP. Hypnosis and clinical pain. Psychol Bull 2003; 129:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/54\">",
"      Patterson DR, Questad KA, Boltwood MD, et al. Patient self-reports three months after sustaining a major burn. J Burn Care Rehabil 1987; 8:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/55\">",
"      Wakeman JR, Kaplan JZ. An experimental study of hypnosis in painful burns. Am J Clin Hypn 1978; 21:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/56\">",
"      Patterson DR, Tininenko JR, Schmidt AE, Sharar SR. Virtual reality hypnosis: a case report. Int J Clin Exp Hypn 2004; 52:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/57\">",
"      Hoffman HG, Patterson DR, Carrougher GJ. Use of virtual reality for adjunctive treatment of adult burn pain during physical therapy: a controlled study. Clin J Pain 2000; 16:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/58\">",
"      Patterson DR, Wiechman SA, Jensen M, Sharar SR. Hypnosis delivered through immersive virtual reality for burn pain: A clinical case series. Int J Clin Exp Hypn 2006; 54:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/59\">",
"      Sharar SR, Miller W, Teeley A, et al. Applications of virtual reality for pain management in burn-injured patients. Expert Rev Neurother 2008; 8:1667.",
"     </a>",
"    </li>",
"    <li>",
"     Burn pain: Nonpharmacologic approaches. Pain ladder treating pain painladder.com/index.php/acute-pain/burn-pain-nonpharmacologic-approaches (Accessed on June 22, 2011).",
"    </li>",
"    <li>",
"     Greenberg JS. Part 3. General applications: Relaxation techniques.  Chapter 10. Autogenic training, imagery, and progressive relaxation. In: Comprehensive Stress Management, 12th, Greenberg JS (Ed), McGraw-Hill Higher Education, New York 2011. p.203.",
"    </li>",
"    <li>",
"     Jacobson E. Progressive Relaxation, University of Chicago Press, Chicago 1938.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/63\">",
"      Edwards RR, Haythornthwaite JA, Sullivan MJ, Fillingim RB. Catastrophizing as a mediator of sex differences in pain: differential effects for daily pain versus laboratory-induced pain. Pain 2004; 111:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34169/abstract/64\">",
"      Thurber CA, Martin-Herz SP, Patterson DR. Psychological principles of burn wound pain in children. I: theoretical framework. J Burn Care Rehabil 2000; 21:376.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14989 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34169=[""].join("\n");
var outline_f33_23_34169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13088947\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10926413\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10927394\">",
"      CHARACTERISTICS OF BURN PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11800749\">",
"      BURN PAIN ASSESSMENT TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11800756\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11800763\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11800898\">",
"      PHARMACOLOGIC TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11801092\">",
"      Opioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11801099\">",
"      Nonopioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11801106\">",
"      Anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11801113\">",
"      Anesthetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38726099\">",
"      - General or deep sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38726107\">",
"      - Regional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38726115\">",
"      Neuraxial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38726220\">",
"      Targeted non-neuraxial blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11800906\">",
"      NONPHARMACOLOGIC TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3133671\">",
"      Avoidance techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133254\">",
"      - Distraction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133268\">",
"      - Guided imagery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133302\">",
"      - Hypnotic analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133707\">",
"      - Virtual reality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104704109\">",
"      Approach technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H810810\">",
"      - Information provision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3133699\">",
"      Relaxation techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133830\">",
"      - Deep breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133838\">",
"      - Progressive muscle relaxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3136378\">",
"      Cognitive behavioral techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13088947\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14989|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/50/25381\" title=\"figure 1\">",
"      Burn class depth skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/61/16348\" title=\"figure 2\">",
"      Adjective Rating Scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/8/6285\" title=\"figure 3\">",
"      Numeric Pain Scale 0 to 10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/46/42723\" title=\"figure 4\">",
"      Visual analog scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/20/26944\" title=\"figure 5\">",
"      Faces pain scale children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/16/32000\" title=\"figure 6\">",
"      OUCHER pain scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/9/24732\" title=\"table 1\">",
"      PAINAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/25/7581\" title=\"table 2\">",
"      Revised FLACC pain score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/40/20111\" title=\"table 3\">",
"      Sedative dosage regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/50/30508\" title=\"table 4\">",
"      Opioids children with burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/50/10029\" title=\"table 5\">",
"      PCA dosing guideline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/54/24431\" title=\"table 6\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/16/40205\" title=\"table 7\">",
"      Pharmacology benzodiazepines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38695?source=related_link\">",
"      Paradigm-based treatment approaches for burn pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34170="Development of malignancy following solid organ transplantation";
var content_f33_23_34170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Development of malignancy following solid organ transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Richard J Rodeheffer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Richard F Ambinder, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/23/34170/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/23/34170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic use of immunosuppressive agents to prevent allograft rejection increases the long-term risk of malignancy compared with that of the general population. Here we will review the general issue of malignancy following solid organ transplantation. The problems of second malignancies following bone marrow transplantation and the development of lymphoproliferative disorders following solid organ transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of a wide range of cancers associated with solid organ transplantation. The most extensive data come from a cohort study that analyzed the frequency of malignancy in over 175,000 solid organ transplant recipients during the period 1987 to 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common organs transplanted included kidney, liver, heart, and lung (in 58, 22, 10, and 4 percent of cases, respectively).",
"   </p>",
"   <p>",
"    Overall, malignancy was identified in over 10,656 cases, which correlated with a standardized incidence ratio (SIR) of 2.10 (95% CI 2.06-2.14) compared with the general population, and an excess absolute risk (EAR) of 719 cases per 100,000 person-years.",
"   </p>",
"   <p>",
"    A significantly increased risk of malignancy was associated with more than 30 different primary sites. The tumor sites with a five-fold or greater increase compared with the general population included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Kaposi sarcoma (SIR 61 and EAR 15)",
"     </li>",
"     <li>",
"      Skin (nonmelanoma, nonepithelial SIR 13.9 and EAR 22)",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma (SIR 7.5 and EAR 168)",
"     </li>",
"     <li>",
"      Liver (SIR 11.6 and EAR 110)",
"     </li>",
"     <li>",
"      Anus (SIR 5.8 and EAR 9.6)",
"     </li>",
"     <li>",
"      Vulva (SIR 7.6 and EAR 6.5)",
"     </li>",
"     <li>",
"      Lip (SIR 16.8 and EAR 16)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other common malignancies with a statistically significant (p&lt;0.001) increase included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung (SIR 2.0 and EAR 85)",
"     </li>",
"     <li>",
"      Kidney (SIR 4.7 and EAR 76)",
"     </li>",
"     <li>",
"      Colon and rectum (SIR 1.2 and EAR 15.8)",
"     </li>",
"     <li>",
"      Pancreas (SIR 1.5 and EAR 6.4)",
"     </li>",
"     <li>",
"      Hodgkin lymphoma (SIR 3.6 and EAR 7.9)",
"     </li>",
"     <li>",
"      Melanoma (SIR 2.4 and EAR 29)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other primary malignancies that were significantly increased, but to a lesser extent, included stomach, oral cavity, larynx, pharynx, vulva, penis, thyroid, urinary bladder, lip, esophagus, salivary glands, soft tissue sarcomas, small intestine, testis, biliary tract, acute myeloid leukemia, plasma cell neoplasms, and chronic myeloid leukemia.",
"   </p>",
"   <p>",
"    In contrast, the incidence of breast cancer was significantly decreased (SIR 0.85 with an EAR of -11.2) as was the risk of prostate cancer (SIR 0.92 with an EAR of -11.3).",
"   </p>",
"   <p>",
"    This analysis found that the incidence of specific malignancies varied depending upon the organ transplanted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, the frequency of non-Hodgkin lymphoma was approximately two-fold greater in recipients of lung transplants, compared with those who received a kidney, liver, or heart transplant. Conversely, there was an approximately three-fold increase in lung cancer among lung transplant recipients, and the frequency of liver and kidney cancer were increased in liver and kidney transplant recipients, respectively.",
"   </p>",
"   <p>",
"    Similar patterns of increased incidence were observed in a review of the literature that included studies from five tumor registries in Europe, Canada, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When all cancers are considered, the average age at diagnosis is approximately 40, and the average latency is approximately three to five years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, the average time to presentation of particular neoplasms occurs at distinct time intervals following transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      KS &mdash; 13 to 21 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphomas &mdash; 32 months, although the incidence is highest during the first year, when the risk of primary viral infection and the level of immunosuppression is most intense (",
"      <a class=\"graphic graphic_figure graphicRef50807 \" href=\"mobipreview.htm?18/28/18893\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epithelial (including skin) cancers &mdash; 69 months",
"     </li>",
"     <li>",
"      Cancers involving the anogenital region &mdash; 84 to 112 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/6\">",
"       6",
"      </a>",
"      ]. The latency is even longer among patients who received allografts as children, in whom the lesions often develop during adulthood (mean interval after transplantation was 142 months for carcinomas of the vulva and perineum in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/7\">",
"       7",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin cancers, especially squamous cell and basal cell carcinomas, but also melanoma, Merkel cell carcinoma, and Kaposi sarcoma are more common than in the nontransplant population. The issues surrounding these malignancies are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=see_link\">",
"       \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link\">",
"       \"Management of skin cancer in solid organ transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma of the eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SCC of the eye is elevated in patients with immunosuppression due to HIV infection. Similarly, the incidence of this malignancy was reported to be approximately 20-fold higher in a study of renal transplant recipients from Australia compared to the nonimmunosuppressed population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506403#H1560506403\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Conjunctival cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anogenital cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers involving the anogenital region (ie, anus, vulva, perianal region, penis, scrotum, or perineum) account for 2 to 3 percent of cancers in transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Lesions tend to be multiple",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extensive, particularly in women, one-third of whom have concurrent cervical cancer. Clinically, these lesions often appear as pigmented papular lesions, but they may resemble genital warts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lung cancer has been noted to be particularly increased in recipients of heart and lung transplants, and this may be related to the high incidence of cigarette smoking leading to heart and lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, the incidence also appears to be increased following kidney and liver transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung transplants are frequently carried out in patients with chronic obstructive lung disease secondary to smoking. In this setting, the incidence of lung cancer is markedly increased, and frequently arises in the residual native lung in recipients of a single-lung transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, in a series of 520 lung transplants conducted at a single institution over a 17 year period, 12 patients developed lung cancer, 11 of which occurred in the residual native lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence of lung cancer compared to the general population is similar to that seen in patients infected with HIV, and thus may be a reflection of the role of chronic, prolonged immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506361#H1560506361\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Lung cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Kaposi's sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of posttransplant KS occur in individuals of Mediterranean, Jewish, Arabic, Caribbean, or African descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/18\">",
"     18",
"    </a>",
"    ]. This is a function of the geographic distribution of human herpesvirus 8 (HHV-8, also known as KS-associated herpesvirus or KSHV) (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Pathogenesis'",
"    </a>",
"    below). There is a male predilection (male to female ratio 3.3 to 1), and the average age at diagnosis is 43, younger than for patients with classic KS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is similar to that of classic KS, manifested as angiomatous lesions predominantly affecting the legs, and causing lymphedema. Although the incidence varies by population, approximately ninety percent of patients have cutaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucosal lesions, while 10 percent have disease that is limited to the viscera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. For unclear reasons, visceral involvement is less common in patients with kidney as compared to liver or heart allografts (25 to 30 versus 50 percent). At least partly because of this, patients who develop KS after a liver or heart transplant have shorter survival than those who have undergone renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of malignant lymphoproliferative disorders occurring following solid organ transplantation are of B-cell origin, most commonly non-Hodgkin lymphoma. In a study of data obtained from the United States Renal Data System of 66,159 adult Medicare kidney transplant recipients, malignant lymphoid proliferations were diagnosed in 1169 (1.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/24\">",
"     24",
"    </a>",
"    ]. Of this total, 70, 14, 11, and 5 percent were diagnosed as non-Hodgkin lymphoma, multiple myeloma, lymphoid leukemia, or Hodgkin lymphoma, respectively.",
"   </p>",
"   <p>",
"    T-cell lymphoproliferative disorders have been described, but are rare. This subject is discussed in greater depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous sarcomas other than KS have been described in transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. However, the small number of reported cases precludes any conclusions about whether their incidence is significantly increased following solid organ transplantation.",
"   </p>",
"   <p>",
"    Leiomyosarcomas due to infection of smooth muscle cells with Epstein-Barr virus have been reported in recipients of kidney and liver transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. These tumors have also arisen in patients infected with HIV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506480#H1560506480\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors have been linked to the increased incidence of secondary malignancies among transplant recipients, including sun exposure, extent and duration of immunosuppression, concomitant viral infection, and in patients undergoing renal transplantation, pretransplantation dialysis. In rare cases, malignancy has been transplanted from the donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sun exposure and skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors associated with an increased risk of skin cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=see_link&amp;anchor=H442687#H442687\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Type, extent, and duration of immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody therapy directed against T lymphocytes (as with OKT3 or antilymphocyte serum) specifically predisposes to posttransplant lymphoproliferative disorders induced by Epstein-Barr virus (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast, antibody therapy targeting B lymphocytes (as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) may reduce the incidence of lymphoproliferative disorders and is regarded by many as appropriate first line therapy for these disorders. There is a dose-dependent relationship between calcineurin inhibitors and secondary malignancies. The same does not appear to be true of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and related agents which may have direct antitumor effects and do not predispose to lymphoproliferative disorders or skin cancers in the same fashion that calcineurin inhibitors do.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The impact of immunosuppression on the development of skin cancer is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=see_link&amp;anchor=H442687#H442687\">",
"       \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Episodes of graft rejection in the first year after transplantation increase the likelihood of developing a secondary malignancy, possibly because of the greater level of immunosuppression that is required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective trial, 231 renal allograft recipients were randomly assigned, after 12 months of standard immunosuppressive therapy, to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      doses adjusted to yield trough blood concentrations between 75 to 125",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (low dose group), or doses that yielded trough concentrations between 150 to 250",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (normal dose group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/29\">",
"       29",
"      </a>",
"      ]. At a median follow-up of 66 months, patients receiving the low dose cyclosporine regimen had a significantly lower incidence of all secondary cancers (23 versus 37 cancers), particularly skin cancers (17 versus 26 cancers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac, as opposed to renal, transplantation requires a higher level of immunosuppression because of the risk of death associated with organ rejection. The relationship between an increased level of immunosuppression and the likelihood of malignancy can be illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of over 50,000 kidney and heart transplants from centers in the Europe and North America, the incidence of PTLD was highest in the first year, the time of most intense immunosuppression, and fell by about 80 percent thereafter (",
"      <a class=\"graphic graphic_figure graphicRef50807 \" href=\"mobipreview.htm?18/28/18893\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/30\">",
"       30",
"      </a>",
"      ]. The incidence was significantly greater in heart transplant recipients, a finding consistent with the greater degree of immunosuppression in these patients.",
"      <br/>",
"      <br/>",
"      Among patients who developed PTLD, renal transplant recipients were much more likely to have renal lymphoma (14.2 versus 0.7 percent in heart transplant recipients), while heart transplant recipients were more likely to develop lymphoma in the heart or especially the lungs (17.9 versus 6.8 percent in renal transplant recipients). These findings are consistent with the hypothesis that the local immune reaction against the graft may be one of the factors promoting malignant transformation.",
"     </li>",
"     <li>",
"      Others studies have confirmed that the risk of PTLD after cardiac transplantation appears to be greater than after renal transplantation, but less than after lung transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/30-34\">",
"       30-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac transplant patients who are at greatest risk for PTLD are those treated with both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or with polyclonal (antilymphocyte serum) or monoclonal (OKT3) antilymphocyte antibodies. In OKT3-treated patients, both the dose and the duration of therapy are important [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, the overall level of immunosuppression appears to be the principal factor that increases the risk of posttransplant malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/36\">",
"     36",
"    </a>",
"    ]. However, limited evidence from animal models suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    itself may promote cancer progression, principally via the production of transforming growth factor-beta (TGF-beta). In vitro, cyclosporine induces invasive behavior of nontransformed cells in association with striking morphologic changes; in addition, cyclosporine administration promotes tumor growth in immunodeficient animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/37\">",
"     37",
"    </a>",
"    ]. Both the in vitro and in vivo changes were prevented by the administration of anti-TGF-beta antibodies.",
"   </p>",
"   <p>",
"    An increase in proangiogenic effect due to elevated expression of vascular endothelial growth factor has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Another notable cytokine with increased levels is interleukin-6, which may help EBV-induced B cell growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from one series suggest that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    increases the risk of malignancy following kidney transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/41\">",
"     41",
"    </a>",
"    ]. Tacrolimus appears to increase TGF-beta levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/42\">",
"     42",
"    </a>",
"    ], an effect clearly associated with tumor growth with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the overall level of immunosuppression is the principal factor underlying the risk of posttransplant malignancy, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been associated with neoplastic development post-transplantation, particularly an increased risk of cutaneous squamous cell carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/36\">",
"     36",
"    </a>",
"    ]. The mechanism of action is postulated, via intercalation of DNA, to be the inhibition of repair splicing and induction of codon misreads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , an inhibitor of the mammalian target of rapamycin (mTOR), suppresses the growth and proliferation of tumors in various animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/38,40,44\">",
"     38,40,44",
"    </a>",
"    ]. Possible mechanisms of actions include inhibition of p70 S6K (thereby decreasing cell proliferation), IL-10 (decreasing tumor cell",
"    <span class=\"nowrap\">",
"     Jak/STATs",
"    </span>",
"    activity), and cyclins (blocking cell cycle activity). Lymphangiogenesis also appears to be impeded via impaired signaling of vascular endothelial growth factors A and C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, evidence also suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , compared with other immunosuppressive medications, may confer a decreased risk of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/40,46-53\">",
"     40,46-53",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Rapamune Maintenance Regimen Study, the relative risk of malignancy was evaluated among patients randomly assigned to remain on",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"      </span>",
"      versus those assigned to cyclosporine withdrawal plus increased sirolimus trough levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/46\">",
"       46",
"      </a>",
"      ]. At five years, estimates for nonskin cancer were significantly lower with the cyclosporine withdrawal group (4.0 versus 9.6 percent); a similar decreased risk was observed for skin malignancies.",
"     </li>",
"     <li>",
"      In a prospective study, 54 kidney transplant recipients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or continuation of their original immunosuppressive regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/53\">",
"       53",
"      </a>",
"      ]. Sirolimus-based immunosuppressive therapy significantly delayed the development of premalignant lesions, induced regression of preexisting lesions, and decreased the incidence of nonmelanoma skin cancers. However, a large proportion of patients given sirolimus withdrew (9 of 25 patients, 36 percent), due principally to the induction of side effects (7 of 9). In addition, switching to sirolimus was associated with deterioration in allograft function in a patient with squamous cell carcinoma and excellent baseline kidney function (serum creatinine of 0.9 to 1.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      who had been transplanted 26 years ago.",
"     </li>",
"     <li>",
"      Among 1295 patients enrolled in two double-blinded trials, the incidence of cancer, particularly skin cancer, was lower in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multivariate analysis of 33,249 deceased donor transplant recipients reported that the relative risk of de novo cancer with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"        everolimus",
"       </a>",
"      </span>",
"      was 0.44 (CI 95% 0.24-0.82) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/48\">",
"       48",
"      </a>",
"      ]. The overall incidence rates of de novo malignancy were 0.6, 0.6, and 1.8 percent with",
"      <span class=\"nowrap\">",
"       sirolimus/everolimus",
"      </span>",
"      alone,",
"      <span class=\"nowrap\">",
"       sirolimus/everolimus",
"      </span>",
"      plus",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"        tacrolimus",
"       </a>",
"       ,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       cyclosporine/tacrolimus,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      In a randomized trial of 120 patients who were taking calcineurin inhibitors and had at least one squamous-cell cancer, the survival free of cancer recurrence was longer among patients who were switched from calcineurin inhibitors to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      compared with those who continued calcineurin inhibitors (16 versus 7 months, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/54\">",
"       54",
"      </a>",
"      ]. However, the number of serious side effects was much higher in the sirolimus group (60 versus 14), and 23 percent of patients discontinued sirolimus because of side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in renal transplant recipients has been associated with complete regression of Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/50,55,56\">",
"     50,55,56",
"    </a>",
"    ]. Sirolimus was substituted for cyclosporine in one study of 15 kidney transplant patients with Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/55\">",
"     55",
"    </a>",
"    ]. This resulted in the disappearance of lesions in all patients by three months, but acute rejection episodes and decreases in kidney function were not observed. On skin biopsy, Kaposi lesions were found to have increased levels of VEGF,",
"    <span class=\"nowrap\">",
"     Flk-1/KDR",
"    </span>",
"    and phosphorylated Akt and p70S6, which are molecules targeted by sirolimus. This suggests that the regression was largely due to the direct inhibition of sarcoma by sirolimus rather than the withdrawal of cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a retrospective review of Medicare claims data for transplant recipients who underwent transplant from January 2000 to September 2006, de novo use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    was associated with a 22 percent increased risk of PTLD (adjusted hazard ratio (HR) 1.22, 95% CI 1.03&ndash;1.45) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/58\">",
"     58",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Because of these published observations, some clinicians use the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    (goal levels of 5 to 8",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    plus corticosteroids in kidney transplant recipients with malignancy, either in remission or being actively treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/59\">",
"     59",
"    </a>",
"    ]. Further study is required to more clearly understand the effects of sirolimus on malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil impairs lymphocyte function by blocking purine biosynthesis via inhibition of the enzyme inosine monophosphate dehydrogenase. Some malignancies, including some solid tumors, have dramatic elevations of this enzyme, suggesting that this agent may have some antiproliferative activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/36,60\">",
"     36,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some population studies also suggest that the risk of developing a malignancy is not higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and may actually be associated with a decreased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/36,61,62\">",
"     36,61,62",
"    </a>",
"    ]. In a study using data from two large registries, there was a non-significant trend to a decreased risk with mycophenolate versus non-mycophenolate based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A principal mechanism of a lower malignancy risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, to the degree that it occurs, may be due to the decreased incidence of acute rejection. This results in a reduced need for increased doses of immunosuppressive agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Coexisting viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least four viruses may be cocarcinogenic in transplanted patients: Epstein-Barr virus (EBV), HHV-8, human papillomavirus (HPV), and the Merkel cell polyomavirus (MCV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Lymphomagenesis and EBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomas are among the most common complications of transplantation; many are related to EBV infection. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31738?source=see_link&amp;anchor=H21103657#H21103657\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     KS and HHV 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of HHV-8 in tumor tissue has been recognized in all forms of KS: classic KS, endemic KS, AIDS KS, and posttransplant KS, with serologic evidence of infection also being common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]: (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of renal transplant recipients from Saudi Arabia, in whom the incidence of KS is approximately 10-fold higher than patients from Western countries, found a markedly higher incidence of specific anti-HHV-8 antibodies in patients with KS compared to those without it (92 versus 28 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 400 consecutive renal transplant recipients, 32 had antibodies to HHV-8 at the time of transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/66\">",
"       66",
"      </a>",
"      ]. Three years after surgery, 28 percent of antibody-positive patients had developed KS compared to no cases in antibody-negative patients.",
"     </li>",
"     <li>",
"      There is convincing evidence of transmission of HHV-8 from the donor to renal and cardiac transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/67-70\">",
"       67-70",
"      </a>",
"      ]. Not only is the virus transmitted but, in at least one series, the tumor cells are also commonly (five or eight) donor derived.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HHV-8 infection is necessary but not sufficient for the development of KS. Transplant related immune dysfunction is an important contributing cofactor.",
"   </p>",
"   <p>",
"    Pretransplant antibody screening would appear to be useful for identifying high-risk patients. If pursued, donor testing is warranted as well, particularly in areas with high seroprevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Squamous skin cancers and HPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of HPV infection in the pathogenesis of squamous cell skin cancers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=see_link&amp;anchor=H442687#H442687\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Merkel cell carcinoma and MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Merkel cell polyomavirus is believed to be a contributing factor to MCC. The data supporting this relationship is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6712?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Transmission from the donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintended transmission of malignant cells from a donor is rare, but may result in metastatic cancer in the immunosuppressed transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/71-77\">",
"     71-77",
"    </a>",
"    ]. In a survey of a single renal transplant center's experience, the risks of having a donor with an undetected malignancy, and of transmitting the cancer, were 1.3 and 0.2 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was also illustrated by a series from the Cincinnati Tumor Registry that included 22 patients who received donor hearts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lungs from patients who had a history of malignancy; malignant tumors subsequently developed in 45 percent of the recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/77\">",
"     77",
"    </a>",
"    ]. Almost all of these tumors were believed to have occurred because of the presence of occult malignant cells in the transplanted organ.",
"   </p>",
"   <p>",
"    The risk of inadvertent transplantation of malignant cells appears to depend upon the type and extent of the donor's cancer. In the Cincinnati Tumor Registry report, although the numbers were small, the authors concluded that a history of renal cell cancer without capsular invasion appeared to be safe, but not if vascular invasion was present. No malignancy transmission was noted with CNS tumors with the exception of one medulloblastoma. In contrast, a history of melanoma or choriocarcinoma was associated with high rates of transmission, with early and almost universal death.",
"   </p>",
"   <p>",
"    A variety of donor transmitted malignancies have been documented including melanoma, and cancers of the lung, breast, colon, rectum, and kidney, Kaposi's sarcoma, and glioblastoma multiforme. In one review, malignancy developed in 78 of 142 (45 percent) patients who received a cadaver graft from a donor subsequently found to have a tumor. Metastatic disease occurred in 36, while complete remission occurred in 9 of the 20 patients treated with cessation of immunosuppression with or without graft nephrectomy. In comparison, transmission of nonmelanoma skin cancer and some central nervous system tumors appears to be rare, and the risk appears very low in donors with a past history of cancer but no evidence of current disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Renal tumors in kidney transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney cancer can develop in both the remaining native kidney and in the transplanted kidney:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal transplant recipients are at increased risk of developing carcinoma of the native kidneys, particularly if they have undergone prolonged periods of dialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. The incidence is approximately 100 times greater than expected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. Why this might occur is not known. It may be related in part to the factors which, during the period of advanced renal failure, lead to tubular hyperplasia, cyst formation, and, in some cases, malignant transformation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=see_link\">",
"       \"Acquired cystic disease of the kidney in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal tumors are rare in transplanted kidneys. A retrospective, multicenter study identified 20 patients with histologically confirmed tumors in a survey of 11 European centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/83\">",
"       83",
"      </a>",
"      ]. Tumors were small (0.6 to 4.0 cm in diameter). Pathologically, 17 were papillary and 3 were clear cell, in contrast to the predominance of clear cell tumors in other populations. All patients were successfully managed with either radiofrequency ablation or cryoablation and without a change in immunosuppression, although one patient developed a new tumor (clear cell carcinoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Urinary tract malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of developing neoplasms of the native urinary tract has been observed in patients with a history of analgesic nephropathy, prolonged exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and nephropathy induced by Chinese herbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=see_link\">",
"     \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recurrent malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of malignancy prior to transplantation may experience recurrent disease. This is discussed below (see",
"    <a class=\"local\" href=\"#H52\">",
"     'Transplantation in patients with preexisting malignancy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CANCER SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to prevent and detect solid organ malignancies in the transplant patient, particularly early stage carcinomas, relies upon periodic screening examinations and strict adherence to prophylactic measures. The Clinical Practice Guidelines Committee of the American Society of Transplantation has published recommended guidelines for cancer screening in renal transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/87\">",
"     87",
"    </a>",
"    ]. These recommendations are summarized in (",
"    <a class=\"graphic graphic_table graphicRef57971 \" href=\"mobipreview.htm?31/42/32428\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific issues relating to cancer screening are discussed below for several cancer sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Similar issues related to lymphoproliferative disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the increased risk of skin cancer in organ transplant recipients, dermatologic evaluation and patient counseling on the risk and prevention of skin cancer should be considered prior to organ transplantation. After organ transplantation, patients should continue to have complete skin examinations on a regular basis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link&amp;anchor=H2294684#H2294684\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Follow-up and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Renal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of RCC is of principal concern in the renal transplant patient, with most cancers arising in the native kidneys and not the renal allograft. Since urine cytology is unreliable for nonfunctioning native kidneys, surveillance ultrasonography (US) or CT scanning has been suggested for routine monitoring. Based upon an assumed growth rate of less than 1 cm per year, and the observation that tumors less than 3 cm in size are usually limited to the kidney, it has been recommended that US examinations be performed every three years to detect early-stage RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/81\">",
"     81",
"    </a>",
"    ]. Others have suggested yearly imaging screening examinations.",
"   </p>",
"   <p>",
"    There is also some evidence that renal cell carcinoma is more common among kidney transplant recipients than previously appreciated, particularly in those with acquired cystic kidney disease (ACKD). For some clinicians, this suggests that an even more intensive screening may be warranted in some patients. As an example, in a prospective study, ultrasound screening of the native kidneys was performed in 561 patients, of whom 129 had ACKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/89\">",
"     89",
"    </a>",
"    ]. Newly diagnosed renal cell carcinoma was found in eight patients (1.5 percent), seven having ACKD. In the whole cohort, 19 additional patients had a previous diagnosis of renal carcinoma and 18 of this group had ACKD. Thus, the prevalence of renal cancer was 4.8 percent in the whole group and 19.4 percent among those with ACKD.",
"   </p>",
"   <p>",
"    Based upon these findings, the authors recommend the following screening approach that varies with the presence of ACKD and radiologic characteristics of cysts in the native kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Independent of ACKD, all transplant patients should, at minimum, undergo ultrasonography of the native kidneys once a year.",
"     </li>",
"     <li>",
"      Patients with ACKD plus Bosniak category I or II cysts should undergo renal ultrasonography twice a year and CT scan for progressive lesions.",
"     </li>",
"     <li>",
"      Patients with ACKD plus Bosniak category IIF cysts should undergo renal ultrasonography four times per year and yearly CT scan or MR imaging. Nephrectomy and CT scan for progressive lesions should be performed if progression is observed, even if category III and IV cysts are not reached.",
"     </li>",
"     <li>",
"      Patients with ACKD plus Bosniak category III or IV cysts should undergo nephrectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion concerning the Bosniak categories of renal cysts is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are no prospective data to determine the cost-effectiveness of such screening strategies among a large population of renal transplant recipients. CT scanning and MR imaging may be more sensitive for early detection. Routine screening is not currently recommended in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    .) Issues concerning the administration of gadolinium during magnetic resonance studies among patients with moderate to severe renal disease, particularly those requiring dialysis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the markedly increased risk of renal carcinoma, our approach is to monitor for microscopic or gross hematuria post transplant using urinalysis every three to six months with scheduled follow-up clinic visits. If this is positive, we obtain a urine culture, an A.M. urine cytology (that is repeated three times), an ultrasonography of the native kidney, transplant kidney, and bladder, a urine polymerase chain reaction (PCR) for BK (polyomavirus) and a prostate specific antigen (in male patients).",
"   </p>",
"   <p>",
"    The sensitivity and specificity of urinalysis for hematuria to detect renal cell is unknown. In the absence of formal cost-effectiveness studies, we believe our approach to be the most cost-effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Urinary tract malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of developing neoplasms of the native urinary tract has been observed in patients with a history of prolonged exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , analgesic nephropathy, and nephropathy induced by Chinese herbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yearly screening for nonglomerular hematuria is indicated in patients previously administered prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy due to the continued risk of bladder cancer. Patients with nonglomerular hematuria should undergo cystoscopy; by comparison, cytologic examination of the urine may miss low-grade lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to screening for urinary tract malignancy in patients with analgesic nephropathy and nephropathy induced by Chinese herbs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=see_link\">",
"     \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend screening all male transplant recipients older than 50 years for prostate cancer with an annual PSA. Although the incidence of prostate cancer is lower than expected in transplant recipients, this may be due to early detection and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alpha-fetoprotein (AFP) and abdominal ultrasound (US) should be performed every 6 to 12 months in transplant recipients with recurrent viral hepatitis, particularly those with hepatitis B or C that has progressed to cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/87\">",
"     87",
"    </a>",
"    ]. Serum AFP has a low sensitivity for the detection of small hepatocellular carcinomas (HCCs) (ranging between 20 to 60 percent), but high specificity (exceeding 90 percent in most series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/91\">",
"     91",
"    </a>",
"    ]. By comparison, hepatic US is more sensitive than serum alpha-fetoprotein (exceeding 80 to 85 percent for the detection of small HCCs ranging in size from 1 to 5 cm). Suspicious lesions should be evaluated with contrast-enhanced CT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of colorectal cancer is increased after the first 10 years in renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/92\">",
"     92",
"    </a>",
"    ]. The implications of this for colorectal cancer screening practices is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H265276753#H265276753\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of lung cancer is increased, the benefit of screening for lung cancer in smokers is unknown, and has not been directly studied in transplant recipients. Radiographically detected nodules and masses are not uncommon following lung and heart-lung transplant and are more likely to represent infection than malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. In a series of 159 patients, such lesions were found in 9 percent of cases undergoing serial posttransplant radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/93\">",
"     93",
"    </a>",
"    ]. The complex issue of lung cancer screening in the general population is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Anal intraepithelial neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increased incidence of anal cancer, screening for the premalignant condition anal intraepithelial neoplasia should be considered in both sexes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=see_link&amp;anchor=H12#H12\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Who should be screened for AIN?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Gynecologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To help detect vulvar, perineal, and uterine malignancies, gynecologic examinations should be performed annually among transplant patients and among those on the wait list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"     84",
"    </a>",
"    ]. This is more frequent screening than is generally recommended for the general population since immunosuppression can reactivate viral infection such as HPV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H24#H24\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Screening frequency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to posttransplant malignancies begins with general preventive measures. In particular, excess immunosuppression especially with calcineurin inhibitors or repeated exposure to agents that selectively target T lymphocytes such as OKT3 should be avoided. Careful screening of the patient and donor prior to transplantation to help detect an underlying preexisting malignancy should also be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H52\">",
"     'Transplantation in patients with preexisting malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following is a general overview of the prevention and treatment of malignancy in transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Reduction of immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction or cessation of immunosuppressive therapy is useful primarily for patients who have undergone renal transplantation, since loss of the graft to rejection is not a fatal event in these patients. Such measures may result in tumor regression in some cases of lymphoma; some skin cancers; KS, in which reducing the calcineurin inhibitor exposure may be particularly important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/10,95-97\">",
"     10,95-97",
"    </a>",
"    ]; and donor-derived malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Kaposi's sarcoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite the association of the calcineurin inhibitors with increased TGF-beta levels and the risk of malignancy, our first approach when serious malignancy occurs posttransplantation is to discontinue the anti-metabolite. This is because rejection is less likely to occur with double therapy with a calcineurin inhibitor and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    than the combination of an anti-metabolite with prednisone. However, some clinicians would substitute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    for the calcineurin inhibitor and antimetabolite.",
"   </p>",
"   <p>",
"    An exception to this is in very well matched HLA transplant recipients, such as 0-HLA or 0-B, 0-DR mismatched recipients, in which case the risk of rejection is low with the combination of an antimetabolite and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . This combination also avoids the nephrotoxicity and malignancy potential associated with a calcineurin inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Kaposi's sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, KS may respond to reduction or discontinuation of the immunosuppressive regimen, and this should be the first therapeutic maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients listed in the Cincinnati registry, for example, reduction in immunosuppressive therapy was associated with the disappearance of KS in 17 and 16 percent of patients with mucocutaneous disease and visceral involvement, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/25,96\">",
"     25,96",
"    </a>",
"    ]. In addition, the substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in a total of 17 renal transplant recipients has been associated with complete regression of Kaposi's sarcoma, as previously mentioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/50,57\">",
"     50,57",
"    </a>",
"    ]. Given these results, we recommend converting to sirolimus from a calcineurin inhibitor in this setting, if there are no contraindications for this strategy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Sirolimus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional treatment options, which may be required for cases that do not regress spontaneously, are similar to those considered for patients without immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Anogenital cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=see_link&amp;anchor=H2#H2\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .) Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , which is available for the treatment of anogenital warts, has not been systematically studied in transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .) Tapering the immunosuppressive regimen is beneficial and may lead to resolution of in situ carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive tumors require wide local excision (eg, radical vulvectomy), with inguinal lymphadenectomy for tumors &gt;1 mm thick, and adjuvant therapy in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .) The management of anal margin and anal canal lesions is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=see_link\">",
"     \"Clinical features, staging, and treatment of anal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Other solid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral malignancies are treated by standard surgical, radiotherapeutic, or chemotherapeutic modalities. If chemotherapy is needed,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    should be discontinued to avoid additive myelosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/95\">",
"     95",
"    </a>",
"    ]. Not surprisingly, the course of these malignancies appears to be more aggressive in transplant recipients, and the outcome is importantly determined by the stage at which the tumor is discovered. Carcinoma in situ can be cured surgically as can many patients with early invasive disease (6 of 11 in one study, with three others dying of intercurrent disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/76\">",
"     76",
"    </a>",
"    ]. In contrast, the outcome is poor in advanced malignancies, with most patients dying within one to two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of breast cancer is less than was previously expected in transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General epidemiology'",
"    </a>",
"    above.) This may be due in part to increased screening. We recommend yearly breast exams in women over the age of 40 pre- and post-transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of posttransplant lymphoproliferative disorders is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Donor derived malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If evaluation of the tumor reveals it to be of donor origin, reduction of immunosuppression may theoretically lead to rejection of the tumor. Although this has been effective in posttransplant lymphoproliferative disorders, there is little evidence that this is effective in other tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of options are available in the management of renal cell carcinoma that emerges from a transplanted kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/80,100\">",
"     80,100",
"    </a>",
"    ]. In those without metastatic disease, total transplant nephrectomy may be curative, although a return to dialysis is required. Some have suggested that consideration may be given to nephron sparing surgery in those with non-metastatic renal cell carcinoma that is less than four centimeters in size and located peripherally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/80,101\">",
"     80,101",
"    </a>",
"    ]. This approach has been reported thus far in only a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/101\">",
"     101",
"    </a>",
"    ]. Metastatic disease should be treated with cessation of immunosuppression, transplant nephrectomy, and immune therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION IN PATIENTS WITH PREEXISTING MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is transplantation in patients with a history of prior malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"     84",
"    </a>",
"    ]. One study found an overall recurrence rate of 22 and 27 percent with treatment before and after transplantation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/102\">",
"     102",
"    </a>",
"    ]. There is, however, a marked variability in the likelihood of recurrence according to tumor type that determines the recommendations for patients with preexisting tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrence rates of 0 to 10 percent were noted among patients with localized renal cell carcinoma, testicular, cervical, and thyroid cancers, and lymphomas (including Hodgkin's and non-Hodgkin's disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/104\">",
"       104",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      A higher recurrence rate (11 to 25 percent) was reported for patients with Wilms' tumor, and for carcinomas of the uterus, colon, prostate, and breast.",
"     </li>",
"     <li>",
"      The highest recurrence rate (over 25 percent) was recorded in patients with bladder carcinoma, advanced renal cell carcinoma, sarcomas, myelomas, and both melanoma and nonmelanoma skin cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liver transplantation has been used to treat hepatocellular carcinoma when disease is localized to the liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .) In addition, renal transplantation has been used in patients with von Hippel-Lindau disease and bilateral renal cell carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of a history of malignancy on patient management is determined by the availability of alternative management approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;No waiting period for transplantation is necessary with low-risk tumors, such as an incidentally discovered renal carcinoma, in situ carcinoma, primary basal cell skin carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/105\">",
"     105",
"    </a>",
"    ], and low-grade bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"     84",
"    </a>",
"    ]. Transplantation should be delayed for at least five years with tumors that carry a high risk of recurrence following transplantation: melanoma (some recommend 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/105\">",
"     105",
"    </a>",
"    ]), breast, and colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/71\">",
"     71",
"    </a>",
"    ]. Transplantation should be delayed for approximately two years with most other tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less is known about the results of cardiac transplantation in patients with a history of malignancy, making the development of guidelines or specific recommendations more difficult. One report, for example, evaluated the course of seven such patients with a history of malignancy, six of whom had a lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/106\">",
"     106",
"    </a>",
"    ]. At two years, only one patient suffered from recurrent malignancy. Another study reviewed data on 34 transplant patients with a history of Hodgkin lymphoma or non-Hodgkin lymphoma who were disease-free for an average of 15 years before transplantation, and followed for a mean of 50 months after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/107\">",
"     107",
"    </a>",
"    ]. The 1, 5, and 10 year actuarial survival rates were 77, 64, and 50 percent, respectively. Cox regression analysis identified splenectomy in patients with prior Hodgkin lymphoma as the only independent risk factor for mortality after transplantation (relative risk 6.2).",
"   </p>",
"   <p>",
"    Although heavily weighted toward lymphomas, this limited experience suggests that patients whose treatment of preexisting cancer is felt to be cured may be satisfactory cardiac transplant candidates. Caution must be exercised, however, since these series have had relatively short follow-up. The importance of a thorough investigation for cancer prior to transplantation in patients with a prior history of cancer, particularly older patients, cannot be overemphasized.",
"   </p>",
"   <p>",
"    Cardiac transplantation has also been used successfully in children suffering refractory congestive heart failure due to anthracycline induced cardiomyopathy following treatment for acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/23/34170/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835993298\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an increased risk of a wide range of cancers associated with solid organ transplantation. The incidence of specific malignancies appears to vary depending upon the organ transplanted. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'General epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several factors have been linked to the increased incidence of secondary malignancies among transplant recipients, including sun exposure, the extent and duration of immunosuppression, concomitant viral infection, and in patients undergoing renal transplantation, pretransplantation dialysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some data suggest that calcineurin inhibitors and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      confer a risk for malignancy that is beyond the degree and duration of immunosuppression. Sirolimus, compared with other immunosuppressive medications, may confer a decreased risk of malignancy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At least four viruses may be cocarcinogenic in transplanted patients, including Epstein-Barr virus (EBV), HHV-8, human papillomavirus (HPV), and the Merkel cell polyomavirus (MCV). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Coexisting viral infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unintended transmission of malignant cells from a donor is rare, but may result in metastatic cancer in the immunosuppressed transplant recipient. The risk of inadvertent transplantation of malignant cells appears to depend upon the type and extent of the donor's cancer. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Transmission from the donor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to prevent and detect solid organ malignancies in the transplant patient, particularly early stage carcinomas, relies upon periodic screening examinations and strict adherence to prophylactic measures. The Clinical Practice Guidelines Committee of the American Society of Transplantation has published recommended guidelines for cancer screening in renal transplant patients (",
"      <a class=\"graphic graphic_table graphicRef57971 \" href=\"mobipreview.htm?31/42/32428\">",
"       table 1",
"      </a>",
"      ). Our approach to screening for specific malignancies is provided above. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Cancer screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to posttransplant malignancies begins with general preventive measures. In particular, excess immunosuppression or repeated exposure to antilymphocyte drugs should be avoided. Careful screening of the patient and donor prior to transplantation to help detect an underlying preexisting malignancy should also be performed. (See",
"      <a class=\"local\" href=\"#H52\">",
"       'Transplantation in patients with preexisting malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduction or cessation of immunosuppressive therapy is useful primarily for patients who have undergone renal transplantation, since loss of the graft to rejection is not a fatal event in these patients. Such measures may result in tumor regression in lymphoma, skin cancers, Kaposi&rsquo;s sarcoma, in which reducing the calcineurin inhibitor exposure may be particularly important, and in donor-derived malignancies. Approaches to specific malignancies are provided above. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with a history of prior malignancy, there is a marked variability in the likelihood of recurrence according to tumor type that determines the recommendations for patients with preexisting tumors. The impact of a history of malignancy on patient management is determined by the availability of alternative management approaches. The following approach is for patients who have received a kidney transplant (see",
"      <a class=\"local\" href=\"#H54\">",
"       'Kidney transplantation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No waiting period for transplantation is necessary with low-risk tumors, such as an incidentally discovered renal carcinoma, in situ carcinoma, primary basal cell skin carcinoma, and low-grade bladder cancer.",
"     </li>",
"     <li>",
"      Transplantation should be delayed for at least five years with tumors that carry a high risk of recurrence following transplantation including melanoma (some recommend 10 years), breast, and colorectal cancer. Transplantation should be delayed for approximately two years with most other tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less is known about the results of cardiac transplantation in patients with a history of malignancy, making the development of guidelines or specific recommendations more difficult. Limited data suggest that patients whose treatment of preexisting cancer is felt to be cured may be satisfactory cardiac transplant candidates. The importance of a thorough investigation for cancer prior to transplantation in patients with a prior history of cancer, particularly older patients, cannot be overemphasized. (See",
"      <a class=\"local\" href=\"#H55\">",
"       'Heart transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/1\">",
"      Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/2\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/3\">",
"      Saeian K, Franco J, Komorowski RA, Adams MB. Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. Liver Transpl Surg 1999; 5:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/4\">",
"      Stewart T, Tsai SC, Grayson H, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995; 346:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/5\">",
"      Pedotti P, Cardillo M, Rossini G, et al. Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation 2003; 76:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/6\">",
"      Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/7\">",
"      Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998; 2:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/8\">",
"      Vajdic CM, van Leeuwen MT, McDonald SP, et al. Increased incidence of squamous cell carcinoma of eye after kidney transplantation. J Natl Cancer Inst 2007; 99:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/9\">",
"      Adami J, G&auml;bel H, Lindel&ouml;f B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/10\">",
"      Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/11\">",
"      Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/12\">",
"      Anyanwu AC, Townsend ER, Banner NR, et al. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg 2002; 124:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/13\">",
"      Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/14\">",
"      Goldstein DJ, Austin JH, Zuech N, et al. Carcinoma of the lung after heart transplantation. Transplantation 1996; 62:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/15\">",
"      Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol 2008; 3:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/16\">",
"      G&eacute;n&eacute;b&egrave;s C, Brouchet L, Kamar N, et al. Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol 2010; 5:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/17\">",
"      Arcasoy SM. Controversies in bronchogenic carcinoma following lung transplantation: type of transplant operation and role of screening. J Thorac Oncol 2008; 3:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/18\">",
"      Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore) 2005; 84:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/19\">",
"      Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998; 12:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/20\">",
"      Fenig E, Brenner B, Rakowsky E, et al. Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol 1998; 21:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/21\">",
"      Farge D. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993; 2:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/22\">",
"      Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM 2005; 98:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/23\">",
"      Aseni P, Vertemati M, Minola E, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 2001; 7:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/24\">",
"      Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/25\">",
"      Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/26\">",
"      Jenson HB. Review: Epstein-Barr virus-associated smooth muscle tumors. Clin Adv Hematol Oncol 2010; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/27\">",
"      Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/28\">",
"      Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:III222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/29\">",
"      Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/30\">",
"      Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/31\">",
"      Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/32\">",
"      Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/33\">",
"      Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/34\">",
"      Chen JM, Barr ML, Chadburn A, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/35\">",
"      Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/36\">",
"      Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/37\">",
"      Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/38\">",
"      Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/39\">",
"      Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003; 63:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/40\">",
"      Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/41\">",
"      Imao T, Ichimaru N, Takahara S, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer 2007; 109:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/42\">",
"      Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/43\">",
"      Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/44\">",
"      Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/45\">",
"      Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/46\">",
"      Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/47\">",
"      Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/48\">",
"      Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/49\">",
"      Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/50\">",
"      Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/51\">",
"      Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/52\">",
"      Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/53\">",
"      Salgo R, Gossmann J, Sch&ouml;fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/54\">",
"      Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/55\">",
"      Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/56\">",
"      Lebb&eacute; C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/57\">",
"      Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/58\">",
"      Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011; 92:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/59\">",
"      Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/60\">",
"      Engl T, Makarevi�� J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/61\">",
"      Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/62\">",
"      O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/63\">",
"      Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996; 334:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/64\">",
"      Munoz P, Alvarez P, de Ory F, et al. Incidence and clinical characteristics of Kaposi sarcoma after solid organ transplantation in Spain: importance of seroconversion against HHV-8. Medicine (Baltimore) 2002; 81:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/65\">",
"      Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 1998; 65:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/66\">",
"      Franc&egrave;s C, Mouquet C, Marcelin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 2000; 69:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/67\">",
"      Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/68\">",
"      Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/69\">",
"      Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/70\">",
"      Emond JP, Marcelin AG, Dorent R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol 2002; 40:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/71\">",
"      Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/72\">",
"      Myron Kauffman H, McBride MA, Cherikh WS, et al. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/73\">",
"      Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002; 74:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/74\">",
"      Pedotti P, Poli F, Longhi E, et al. Epidemiologic study on the origin of cancer after kidney transplantation. Transplantation 2004; 77:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/75\">",
"      Armanios MY, Grossman SA, Yang SC, et al. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro Oncol 2004; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/76\">",
"      Penn I. Donor transmitted disease: cancer. Transplant Proc 1991; 23:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/77\">",
"      Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery 2001; 130:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/78\">",
"      Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000; 70:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/79\">",
"      Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/80\">",
"      Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/81\">",
"      Doublet JD, Peraldi MN, Gattegno B, et al. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997; 158:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/82\">",
"      Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002; 61:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/83\">",
"      Cornelis F, Buy X, Andr&eacute; M, et al. De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation. Radiology 2011; 260:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/84\">",
"      Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/85\">",
"      Wu MJ, Lian JD, Yang CR, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004; 43:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/86\">",
"      Hung YM, Chou KJ, Hung SY, et al. De novo malignancies after kidney transplantation. Urology 2007; 69:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/87\">",
"      Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/88\">",
"      European Best Practices Guidelines. Nephrol Dial Transplant 2002; 17(Suppl 4):37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/89\">",
"      Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007; 2:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/90\">",
"      Scandling JD. Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening? Clin J Am Soc Nephrol 2007; 2:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/91\">",
"      Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/92\">",
"      Park JM, Choi MG, Kim SW, et al. Increased incidence of colorectal malignancies in renal transplant recipients: a case control study. Am J Transplant 2010; 10:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/93\">",
"      Schulman LL, Htun T, Staniloae C, et al. Pulmonary nodules and masses after lung and heart-lung transplantation. J Thorac Imaging 2000; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/94\">",
"      Haramati LB, Schulman LL, Austin JH. Lung nodules and masses after cardiac transplantation. Radiology 1993; 188:491.",
"     </a>",
"    </li>",
"    <li>",
"     Penn, I. Why do immunosuppressed patients develop cancer? In: CRC Critical Reviews in Oncogenesis, Pimentel, E (Ed), CRC, Boca Raton, 1989, p. 27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/96\">",
"      Franc&egrave;s C. Kaposi's sarcoma after renal transplantation. Nephrol Dial Transplant 1998; 13:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/97\">",
"      Duman S, T&ouml;z H, A��&ccedil;i G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/98\">",
"      Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997; 133:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/99\">",
"      Sheil AG. Donor-derived malignancy in organ transplant recipients. Transplant Proc 2001; 33:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/100\">",
"      Leibovich BC, Blute M, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/101\">",
"      Moudouni SM, Tligui M, Doublet JD, et al. Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys. Transplantation 2005; 80:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/102\">",
"      Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/103\">",
"      Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/104\">",
"      Trofe J, Buell JF, Woodle ES, et al. Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation 2004; 78:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/105\">",
"      Otley CC, Hirose R, Salasche SJ. Skin cancer as a contraindication to organ transplantation. Am J Transplant 2005; 5:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/106\">",
"      Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/107\">",
"      Taylor DO, Farhoud HH, Kfoury G, et al. Cardiac transplantation in survivors of lymphoma: a multi-institutional survey. Transplantation 2000; 69:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/108\">",
"      Ward KM, Binns H, Chin C, et al. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 2004; 23:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/23/34170/abstract/109\">",
"      Levitt G, Bunch K, Rogers CA, Whitehead B. Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer 1996; 32A:826.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7304 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34170=[""].join("\n");
var outline_f33_23_34170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H835993298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Squamous cell carcinoma of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anogenital cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Kaposi's sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sun exposure and skin cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Type, extent, and duration of immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Coexisting viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Lymphomagenesis and EBV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - KS and HHV 8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Squamous skin cancers and HPV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Merkel cell carcinoma and MCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Transmission from the donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Renal tumors in kidney transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Urinary tract malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recurrent malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CANCER SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Skin cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Renal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Urinary tract malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Anal intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Reduction of immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Kaposi's sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Anogenital cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Other solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Donor derived malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      TRANSPLANTATION IN PATIENTS WITH PREEXISTING MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H835993298\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7304|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/28/18893\" title=\"figure 1\">",
"      NHL in transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/42/32428\" title=\"table 1\">",
"      Cancer screening in transplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=related_link\">",
"      Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_23_34171="SJSTEN risk specific meds";
var content_f33_23_34171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Odds ratio from a case-control study of SJS/TEN",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Medication/medication class",
"      </td>",
"      <td class=\"subtitle1\">",
"       Odds ratio",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethoprim sulfamethoxazole &amp; other sulfonamide antibiotics",
"      </td>",
"      <td>",
"       172",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlormezanone",
"      </td>",
"      <td>",
"       62",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aminopenicillins",
"      </td>",
"      <td>",
"       6.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quinolones",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cephalosporins",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carbamazepine",
"      </td>",
"      <td>",
"       90",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenobarbital",
"      </td>",
"      <td>",
"       45",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenytoin",
"      </td>",
"      <td>",
"       53",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Valproic acid",
"      </td>",
"      <td>",
"       25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxicam &amp; NSAIDs",
"      </td>",
"      <td>",
"       72",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allopurinol",
"      </td>",
"      <td>",
"       52",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Corticosteroids",
"      </td>",
"      <td>",
"       54",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The odds ratio for exposure to specific medications in patients hospitalized for SJS/TEN compared to patients hospitalized for other reasons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Roujeau, JC, Kelly, JP, Naldi, L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34171=[""].join("\n");
var outline_f33_23_34171=null;
var title_f33_23_34172="Clinical findings in caudal regression syndrome";
var content_f33_23_34172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in caudal regression syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexion contractures of the knees and hips",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip dislocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic deformity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equinovarus, calcaneovarus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent fibula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scoliosis, kyphoscoliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of or bifid/fused ribs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndactyly, polydactyly, absent radii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pierre Robin syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheoesophageal fistulae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal wall defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malrotation of gut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duodenal/colonic atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inguinal hernia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal agenesis and dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific hydronephrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated ureters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic ureters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vesicoureteral reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fused kidneys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent bladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vesical/cloacal exstrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectovaginal and rectourethral fistulae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transposition of external genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypospadias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureteral atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central nervous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelomeningocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventriculomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial clefts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strabismus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boulas M. Recognition of caudal regression syndrome. Adv Neonatal Care 2009; 9:61. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34172=[""].join("\n");
var outline_f33_23_34172=null;
var title_f33_23_34173="ACST any stroke death";
var content_f33_23_34173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Any type of stroke or perioperative death in the Asymptomatic Carotid Surgery Trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 271px; background-image: url(data:image/gif;base64,R0lGODlhvwEPAeYAAP///wAAAAAz//8AAKqqqjMzM+7u7oiIiHd3d7u7u/Dz//+AgP9AQP/AwODm/6Cz//+IiN3d3f8REf8zMxFB/4ig/1V3///MzGCA/0RERBEREaq7/zBZ///u7oCZ///w8MzMzGZmZlBz/yIiIneS//9VVaCgoLDA//93d/+qqtDZ/8zW//9QUP/g4EBm//+goHCN/8DN/+7x/5mZmf8iIiBN/1VVVTNc//9ERP8QEP8wMP/Q0Jmt/xBA//9gYCJO/0Rp///d3f+wsJCm//+QkP9wcP8gIN3k//9mZv+ZmbvJ/2aF/+Dg4P+7u58jcC8pz++Dj++zwKBzv2Bw7wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC/AQ8BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6errxgUHgxkBASGCCRoBIyCXDuz9/s4J5L0DcGCEgQgaCADQ8A5BAUsOBDz4R7GisQwDbSAQhBFEAAMAAl5yItGiyZO8MHIcmCGEyJABIlhiIKXkIAUoc+pspRKAxpUeQb4sJK9oUUQsiDwQwLQpBn47o0oN1bPgwYQLGz5sFADRggUAoApygEHA06lo01YKKG8ER3n0/0Ley+eo6yEiLBCRNStWrd+/p+waasBA0d6zgBMr9iS40I4cjPZy8BBjseXLkxoT+jCgRSMHJ2DUECBiiArMqFMb0kzIh49IDh5g6NEDw4O+qnMDZj2oRWdKKoaIEFADxgncupPv5D3INaYYHjjYVE49J3NBvndoUtEDRvXvJq8LepHjgyYHHETgBM+enXhBPnRsUiCCA/L2+MW9F6Tj9SYYPZyW34D6NfJBDi9wspQIJxDoYDf7CbLDb5s44EENNXhw34McPhOhICyA5ckJwzHY4YnQfAiAEEaEYiGGGqIoYzIqAmCEEKOQKAAHxq0344+/1LhAXqQoEJp0PJ4gIP+QTN5So2/mnWIkDNJN1OSVs9QIAAsJrrKUlViG2YqWLxDp5XRiphlYJL51eSaYasYpipYAPEZEK1/KqScodNZphH9v7inoJn0C8IEOLESpylI1uAADZUsOKmldlXzAgg6KpuKACtDB4MJoLpg26aiJFNqcEdrFYiQGGGJwHKmwAmDqIETkkOpmrgTnAl+xTjrrIC8MIOywwrrZymEb9hrmr4NkKmEOgLqCrLJyMqvIoZjGIhkGQ1RGLZbWLuKDrbIoEMMQGCDJbQw+fntiuIsEawQDC7zQgLOtnJuuAMm6ix+8i3ywgxBDMjBADgwUsUADnr3igQv+vttKCw0sUAT/AzkMwECIQuyA7ygK1NBgxA8CfMkHDbywAANGDOBDw6acUEO7JP+bSws+uAwzKS54UDOBJnuCM7FEE6tDEULsPElEPN72M3tBf/LxZhUb/CcRt0Zirgci0CYCZTQ/jVrUr+yAlxEIL1xJbFQK4LPYqpEtSwsvFKHDwQwkXG8DDUCiAgccRAr3YnLbQnHFBd89gA4bf8W30oN44LZaEgzQwTBBSIADKyUMkAQpBigEQOiqFP4L3ypfjPHiSO/8d+DXVC4sBKBU3gEKA9BuCAQDoNBIEhMI6/vuwl7Ou7AlCHIBDQNMcPkFA1yAyAQSXA4ABLKjcAH0xKZAyAXBD5A8/yEpEO07+MgPQgMNpBDw0egBiL4mOiivPMDVqUre6KMxqBD2MsGTXu0spwjeDU8R5RvfIcpnOwCgwHu4ox0OJgAACdBuAgosRBN6J4gECgIJEIAeBQ9Bg+oZEBHM814JO3DC63lOFCEoQAAKQMP4pcJ0yzAbC9BGryhwygOeGo3gABg9AJRvAsHDwfEuKL7Z4aB5xhsW7TrwRAnYjne0k534uFe8CzxxADgIAiGeyDwJfI4QmcMeAQeBBA5isIIlSIEZK4cD6wmCd024Y/O0p7zmHUKEAAAk8ZIHSEEGQXyikKFRMlA6i9DNbsJCWN6c0AMofEUIfGMYMgJoRDAC4P+JSTgk+4LXhA2yr41JOCHzgtC5LFoOi4RgXhNauMIkDAAJhLBd5iRAiA7QAJcN1GMRJ1hBCEwABTQIY+4I0UYxAoCKw5JACrhYvEF4UJC9rJz0rulHQUhghKFIQAEMQM5V4JAah2uAEKbwhK/kLW8ZY50QpqYLTnqwcynowAB4GUBARrBz3ePkFZeJu2Gl4ITU7KYgVgkATgqTWB2A5jIDybwJYK8DEvBdRpk5AGcOAgKdwwE2v+fHkQoCd7gMZEkV+s32IeClCJAJKs6ZDQ5g4BAfEAIkjzZPX9gTkfjUJz+j58/c8S6lgnii9wYKAd5tDp9HXagEPEqICGaOffj/zCUBK2dGEtIumYfUnR7z6EAUXM6WSDCp+kzIwaxCr3prZSEHAXDIDH7CfUaRnyloig0F9ABOhsgpJO/3Th98ZW+Pe4UWIXDPAeRznw0lqh8j6MJhXSAIFWVqB4L3TcdutotfRCQhACpSAGR1EA3UImQ/yj4j0lGDc01BQW+p0u59L3zjy+oTDxhI3H70haJAQAAOQIDiguQRCRhBADQwA0EoVx6MZARfsaECfj1iB5kkwmFZ8M54ImoBSWMP9eyoivWRYgbvmwRDYAKSETT3EdPFBgZu2omUrSxjDPABEe6VnMxtbhWdO6MoQKABjbxUpo0wwHAFgZXnFgDBiojv/zUi0i9MoIwIPjBY2uxFz8FBAq9F0SsjDiCPe8jPAAWwAVcAM19UtIBglxrAnTxsidAV17iT8Ig+BnGA6BLCKEYBDIVZsQMjJIrGlkhAAiKQgElEoACMTEAGyOmOFbOYvquwFKqQLAkUzxC9EGYEegNgA5A8GbrHXYSEscG0Hq2CCAPgUoe5TAgSZ2CcNpypYkDTtiT9LxR0Y0GcXzBnCwvKIQR4cJ7nZ5kpIck4FebEB8o0aEWlM5PqPKymV/bOTsdTWFlT0wE04JAQxOSGuXG0AIY4ikkLeliS7HTeNn1YTGI6sYJYgHz2pMh5NFI5Q+DAn4uhAxHJyQAHQMB7Uf9NHUc1Y0LCmlenDatpe2EacuB5cnMR4GNGJ8evI1tGlLCLae1qmrueHlahUVMQQXhExKRYszlO0INhb4NL7XGIIBQM71HI2xyeIkeZ2oNeBBDA1GGON3gUwIEhFMLe0+CMJBVm7eT0Oi56Bk91m9IUVl/jcF/hruIYF6KFaVIxyV52xhdeiOigA3UWg2fRZk7zmhMLHOJsMiv+7Y/J0BkV7x4ThzbuAhdgwAOUiYEDIP5zSTzZwDFl9oMU4IAYQMcDGCg6UyLd9EeAWB79nhOWHtZ1TdiYAMRN816xFLJwl70SXi4AmKXeJJkx/e2KsDOewx4KnkulZ3ivBKIVzXf/PokpIiJ4wN0DX2dSFwDhdL9SbEqkeMY74uK/VpMCHkD5xW9CBkAQAAU2YQEBbKAWR6AAEFhReh6oAtnKNqegNt/5S5S+KSRIRAUEUAFOlP70hJDBD0ZPiNCvoBAy4LgAbgAAHvyAKUA4QvOZYgFBVOAHibgBBWRgfQowhQQrWIHygT8I4RO/EDzwPu8FkX6m9F4QP8B+KiKQctlLivakqfwkfg+A3a/+ECRger4ngIMQgKI3CBvQFMeHCKVHAkcgANjHAwJQfRRAAkogAEogAxTwfoZwgbkHAAlYfQCwBBUgfswHgExxfoNgggDweyzIf/0nAK53CghRFBjnbffH/3n553mCAIM3gIEycHs/sAG7931ByBRDmHyqJwBKGHoy4HzUJwhLkIIESAgUoIItKAALaAjiJ3/PtwQByAPJV4K8RwI3UIRLUAi7pwTWt3zgJwgsmAhXaAi7l3t1WIcx+IEPKIKmgAAMcXABoHM4OCr4l3iLB4O/93sPiH38p4gQmHxNAYlMwYJTyAO7V30waIVYWHpbWAg/+H5FKABAcHwVeIEbsIG8J4FsOAhTKH0AAHpNQQEbIH4cx32FMIeFEIC9V4e6mIeDQAEnaAozsBX8FnmxUoj6lwg+qIXqF4n814xMoYSCII0xyHEk0IuZ+IubqIWHkIAnKH6rt3sRSP99FnAD4jeLVTiCAuCKg1ABpTeKy6cIuEgIeHiHAmCH9/iLwVgKBAZTAXBgg6gs+Gdv/Od/WTiDPSiArVd+B/iKDRmHbZh7oUd+2lgInJiQwPd8wHeBzNeFhCB+K/CAFaCK9IiBgnCN3CeBSwCRhzCPLhiPE8mCEykIe4gKXxdiAfktHOB2hnB77jeNPjl6/HeEKUiN1Nh8z/eToQeM6WiAP5mATYGJArh7+1gB6hd9xSeCRfiBg+CBgrABTpmGtNgUFOmU68d/7bd+zad+HLh7CFkKZ3djBKB2/vY0MOAd/6B9trgK8ZcNfgceJ8ABFJF6/6cKC4kNf/kdCkAaPGn/eWL3NC+SIVznmJaQmO2hI6EymdRiAwdAlwpHY7TXAzzicf4SD6S2clx2AqxSA64iNiBwACqWkzSmAlTSA4boLkrGZJn3dg4wBLuCAd4CK3E3d6gZeBYimoA1KHpXjMVpeQ/AAT0QI4rAg/kxeBGwaGtHmYQQA2WhfN6JJj8yaqV2as2pnYzAHVgGJJhnjObJCAwnbEwCeyonm+2pCLNBmg+Sm4JIn/WZCEthU91CnbkxnOTJn/2JCOaCLtKBn9+xnNhZCpZZMw9Qbw9inQ/6mQdqCenyIOL5eAXaCMm1XO9FYjPkmYcQoT9jUw+yno+wXgFhADoGAAWwEdKVoZjg/1dWIqCLIZ+RoGADkRAHsBU9ZmU2agkbt3XtkXOUQKImNqQE4RY1WqSXsB5kxx5BZwk6FqSC4KQ/BmTyIKWa0Hbs8XQwlXCM8GSMFKMzSqRgegl2Bx43WXiGMGZltqXyME5s2qaWAHjUgXZxOZfsqaeSEBGN4gEPEJyogWjpZX+COqUx8AAPMxq3eRkkJkM0REP7CaGN6gnIqKMVYQDxAGRyyhibCgr4x3Ge2g/iRE7lFKil6gmJpxhLtnOvWgqcpxhryqi1GgqLKQBFd3RJt3RRkau7uasuYnVIl3W7wis5QayuaqykMC034Q+hk3ajSqrQeizdyXHJeQ7uAxLMaf+g2QoyhICe6xBDM1RD18oJKDqu75mq1NBr0FWs4xoL95kOq9qqz1qvrMAojgIpmkkNBABTUVee/PoKCvBDQQSe3BCn+3qwsZAn3yBcxIVjBguxtLAUAfsM6GWi2YmxurCxz0BgUGemjwmyD+KwF4uy4PGnHtt3LNsh+kmvMcseBGqyMFuzA+Kg60ooOjsgFtqzmtCuPxsOHQp5K1u0usGi4qq0qMGjNOu0uvGyHyu1fVpgmdq0ViurzzUCnfmwW3sZCSBcF1qXYascyBaqGpC1Znu2uoFXGEG1hue2A5oAB7BjcvsJREu31KBgCJBz7iO0mbC3fCsNfhu4gQu2hTv/FYcbP4mbtIuLFgrmpYKLCYQbuc4wuaKquJi7E6z6uVHbuXtyuaKLFqRbulJxuqi7HKvrK60rKar7utsQov/oXEXRbaUiu/mxpu4jE+4FCbGru9gQQyCQXO11pzj7Y8KbpB46EPuWYnm6vMqBFQaAFTyGu7LipcErvdRwmgRGAFJGZc4bYdz7HfYgDxtxZgEwZdFbvkyyve6bDoLBBPH7voJgAgFAv/U7I12Bvyawvz8SAP4LwAEswACgvwTcIQOMvwicwASywAbswA4Cwf8rwQ9swANswQNCwRo8IEyAwV/awR4MAP4LvyKMDQNswidcDRmswissDR9cwbLywu3R/8AuTMPVcMM4PA06vMPAEKo3mLs+nBhWgRCj2sNDzAs/AQA9Qb5J/Bc90RJR+sRqscRNLAjai8RUjAtFbL1OvMVpAcTtC8ZjQ8bKocVmXAxonMbDsMZsHAxZHMdyPMd0XMd2fMd4nMd6vMd83Md+/MeAHMhx3B6ke7qGrAuHDDWIvAuJjAuN/B2FzMiSnAuPXB2RvMiY7MiTDB6XTMmb7CSfbMmZrMmjbAuVTB2dTMqevMqs/Mau/MqwHMuyPMu0XMu2fMvce750YQsIwbaxQLa7XAtq68uwQGLE7AqmdhTUsV76VgskesyuYAP6YAOxiQvNXAtjBs2sEAJBnBxBAf8TjqzNr4AA1XwLNtDNsEAACRGIt5DMIyDOifESAZG8YwLPrGAP9NwK6DUC+ZwKAbFk7JwLIaAB1PHNQ1ELAX0LMxDMXAyls5DMRWHPqnDQusHMW2HKEo0Kd5a3rPBkMuGHuHCdGW0KBaAPIYC9qqHLO0YLJOprtXCdRtHPqGAANtAWI20KIm3Od7rSuNzTPv3TQB3UQj3URF3URn3USJ3USr3UTN3UTv3UUE0MBqBcClGpUU0O+xwBynXTVx0NpunSLf0OLT0CCiFDNT2wRVHOXX0MNWgQBFG7yoVgdiajITZDa+0MppYRokoAoWrXMqQPoFoU43vXxkCxdnqD95A8AB7xEH9NCO7j0IRd2Atmp0Xxmnfq1wGgDy1dAJUb2Z792aAd2qI92qRd2qZ92qid2qq92qzd2q59DIEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Risk of any stroke and perioperative death in ACST. The net five-year risk for all strokes or perioperative death in the CEA group was reduced by nearly half compared with the CEA deferral group.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34173=[""].join("\n");
var outline_f33_23_34173=null;
var title_f33_23_34174="Finger clubbing cyanosis";
var content_f33_23_34174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clubbing and cyanosis in Eisenmenger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clubbing and cyanosis of the fingers in a patient with Eisenmenger syndrome due to an atrial septal defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi Connolly, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34174=[""].join("\n");
var outline_f33_23_34174=null;
var title_f33_23_34175="HSV gingivostomatitis";
var content_f33_23_34175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary herpes simplex virus gingivostomatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 220px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADcAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKAFpKKKAFopKKdwClzSUUgHAkAgEgHrSD1zSUU7gOyQCATg9qUZIJyc0ynce9CdgDJHSlJJOaBs77qDt96LlW8xAeevFSJJsJZccgjBqP5fU/lRkZ6Z/GmptaE2EyaOTTt2OgFISSeam7HoO2Y+8QP1pQ0a9F38fxcVFRQPmtsh5ckYzgegplKAT0GaesTN0paIEpSI6cFJ6CtG0015SS3AHrWnBpBK/dJPNQ6iWx0Qwsn8WhzyxMT0qzbWMk77Y0Yn6V22neFZJFVmUD6ium0vQUtV2kLu9DwTVxUpblqjFbannlt4anlK5BCkZz/9arjeFpIycjI7HPFelW+nouCFVQTwOwqVbFJHWAAdejdz7VXImbRptHl6eGJ2GVicj6U2Tw5IpI2sMDPNevQaeYiMAHB+4Tnj69qq6gI2UugUMQVKYzmmqKsVZ3PIZtCkCF0yVHWs2XTZUzlB+FeuLp+I+D9/qpHes6+0yMtujXjpyKn2diXC/Q8sa0cDJQjHtUDRFa9YtPDaTMJNgbJ2lfSmal4St41ZPKHmYycD19KqNKVrnPOEb2SPJyCKbXXap4f8hcoD6/T61z1xbGMlWGDUN8ujM3QdrxKVFPKMD0plMxaa3HKSrAqSCOhFa9hewzvsvdodgAJOx+vv71jUUmrlQm4O6OtkAtkNvqQM1kxBjmz8yU3OoaKM2DgxSAYdBndWTpeqm3XyLkGW1PVT2+la1tePpaHZ+/sJfmjyd20+lCk4s0lCM1zRV11RylFLRTMBKKkKHbleRTMEUDaa3EopaAD6UCEopcH0owfQ0BYSinBGPQGl2N6UXHyvsMoqQRse1OEDnoPypXRShJ9CGitCDTZ5PuxOT34q7Dos7j/VnPak5GkaEmYVLgntXS/2BOFyUPBpDoM/JEbce1Tz+Rf1V9znNp9DSYOeldL/AGDcMOImIoXQ5eNyHmj2nkP6r5nOCNj0FO8lsdK6iHQ3Yt8hwO9Xk8PsQAEGcZpc7eyLWFilqzi0gZhU8VmzkALXf2XhbfjI5PQZroNN8KRkf6vjOOOafvMPZwh0ueX22kTykAIRz6V0OmeFZpiCIz+WTXquneFYychVO0Z5HStF7BbfAXEY9AOtNUr/ABM1hd7I4oeGYYiQjAIRwEZivQZHOO9XYNGRF4VT64FbjoGlLAKRgjjnmp0DIShZPkxzjnHpxVvlWyOiNJpambAscOxeh6bs9KkIjZ0IZiAcZBz+dEpXzCTjPcgU+QhVAQ/ePTOQaXOaqkkQNAy3BCjAPIG3rVoxEWzltgIPBCn+lQMfk3oxUhs9en4U9romNlZsZHYUKRTgTzSOICAFZHH4jisWQCKdgPmXPTpVuWQNGQAN3QYPaqhXKhu+f1pyn2FGmSZXDZbg54I6GoVh81woHPrilIzhQM7u1XYYssMZD525zRGfNuJ07Gzpll5VvulRSqAjnuTWbrsiQiMIoyBkEcVdmuWt7QBmYHHr39a5PV7tpHxuJ9cmtp1lFaHOqF5XMTVnErMedpzkE1xmqKpY4GfQeldLqchCbR9ao6VpRvLoO5/dq3O7vXG5Oo7CmlDU5JoWPIUn8KrPCwOcY9sV6Pc6ckUkmwfKWOVZARWReaYrDhcAngGtVG3U5pRU90cUVIPIptb11puGITk+lZk1qyk5BBpcxjLDtfCVKu2OoS2YZUCujc7XGRn1qu0TD0NRkYNPRmS5qbvsTQbGcBxxmtddFeRd0GHGMj6UtppZljViDz6V1OgWMsDqhBIAGc+lS5W0aOqENDmF0aYMcqcYpraPJkhex5yK9Sj02NlDFRx1qtfadGp+UdehqLHTypo81/siT0P5U9NElzzkfhXfPaxrHkjpx0qWCzicLgE/jVmfIcLF4ekf6VZXwtJjOTgdRXfxWZHRcduOtXFtwYyNvzCqshckjzlfDJhIO47lOQasPoKzuDKo8w9SO9du0BAOV4qr5fz4PAB9anmRXsXuYCeGIomAePIPtWpaaBAuP3Q4rWjVvLCmXco5x1NW7SPLAsCQOnbP1rS8SfY9yC10WAKDtA9T3NWpdGCICig+wGa17ERl8OH2gYwvrV2OEqpOMHtSdlsXGm1ucgdOCHcByOzHkU5Iov402j1H9a6C4SLHIAfOSe5puveHtU03Tor65txHaTEFJFkVhkjIHBJH40vaaao6o04uyMMQoWXCrgcDiq91bIJMhThM8/WpFkIOO56E1ArtKxUA/Mc+tYTraGywvUWO2jaM4C5PXFXLe0j8vtnuadbW7vjA6ccDFbNtpzggAEHOSBmlCTexnOnGJDp1gWYBE4966y1s4LWNWfBY8HnBzWeksVoqqx+YDJxz+Favhy68OTLct4hvLqKfDeUiLiM8cZIyc5ro1ijlcOZ3sQ3Mka/ckQMfQ4LfXFZN2wywViTjJ5zn6GoopBM29SSW6Kf51ZubDy0jZbmORpF3FQ+So9Gx0PtWMpSR3QpxjoZ587buXczEY4A4FVGVoldnJDNw3f8AGtqSNI4ldTz1I5qmYw6Haic88ntUN2V2bxRn+XI4aQMNvtxVe7YiQEyDjGOMfjWkRIo2vwNp6mse4iuJX2wBi3P4ipnK0TaELsteZjkHKt2z0qGdsqMEHHHBqHdLHGqeXjtg9RTWbKHaG54Ix096qNZSWhlKnZjpn3YX8sUFfkIzjHPJqupLFR371fsrZZZSj537DhQeWPtUyqXY1TSRDCp272AyeB71oQOY8fLhVJwT3qNo/mURgEYxgntTrxgiAJ1UYqoTFKBS1a8JOSciucnctnPfmr93KWkOcbazph0POCPyqXPmZLhyoy7qPzZfrxW1bQpbwRqpOBgj6/Ss3ABHPJPQjtU00rbRt4wAMDrV058t2ctSlzD9T1GG2j3uVLH73FchfeJYy5VImcZ6niruqQySht2SD2rk7+AwsQwGeorRSk37xxVfdXuGousRydEIbPQ1MSlxwyqc1zKMVbIrc0hg8gwc565puNmZ0qvOtdxZ7DcmV4aqM1oqxqzsS5JBTHT8a7JLQEYxnPeqt1ZHgquT3p7FOKlubGmWyGUKRhVG0CuksrZEbOAT/MVj2qeWoJ6nmtuzuFJUHGRSUlfU1p0rK5d2nbxxVObJfBANX1dScZGMVCyoZDk59KppdDRqyMiaMhiQMgHpU0JAYkLtz1qSQASdOacAPpS5TFyLUEnyHIHPQmlWQh9zZPNQIC3TpUmG4LfgKhs3jawy7kycDOc9KoSMzMNoGO9WXH7wnPTvToUG4EgY9KizbNFJJEthbvuJPyqB1rbsPJaNwVJOPlHqfeqESNKcnOD2FakMZjiLheRW6ahsZcrmyaFUtwG9OtTG5YggDgccCqRceWSzcY6VTkuXibKZwf1rGU7HZCimWbpCXJG4Hsfeq8005tfsrlTBvMh2qMkkDqeuOOnSpbW9WUrG/AJ5PHH4mtLXdGm06/FrKyMzxq67JA4w3TkcZpp8y0NdIuzOXltCrfKhIPQnsKsWdkITljtHepbyKaCcB1+bJ6cjjirFlYyX5kKYIiAaRjn5FJxnHfHWs1TTZo56aiw3VvbEiP5m7nFSHWZJEYRAhjxuz2+lbWhjwhZfaLjVpLzUZoGdI7aOLZFOM4Vt2cj1wcVma3qml3VvbjTdFi0+VATO6Ss4k54wD0ArTlcVuc6cZStyv1M8XYALPjHXnpTTcBjlgOnOB0NNhv7SGeI3Fkk6BgWjZyu4A5wGH3cjg4rRj1XSnufn0CIW7TGQpHcyBtpXGwP6A/N068dKXPfS5ryqOy/Iz4r90AxhSDnOP51bjvZXO9t2AdvTAzS6ReWtnqaTzWXnQIzMImOSRg7VJ79eTUF9ds2WYRoJF4VRwvGMj34NRdl+72NCKy1G6dBFCx83lWI4Pp9Olddp1vp/hXUp4vERju0ntyFVBuKv3yPrx+FZPg6y1/WvDF/9hIWK1kR4ZH4Z3HAVT7cn612nhfwRpM1t5OoW9xqGouN1xchiEVu6hvrnpWbZhVrRSab+48uMwKAD+H7pNV4JY0aR35yCMV3fxP0PQvD1hGNPPl3Uz4WJHLDj154xmvMpnfA7U5TNqc1OPMh1y5eXKZAqrcT4dWH3h1zUiRsMjPUflVMws02HbHcHtUtO2w+ZXH+YJGXHBPXjoa0fs63cAz1X7uP1qCxs5bphHbo0kmCQPoOTWjaqsKbmIYkevAqXTctyHV10II0KkcBVH3QDnFOnUOcgc1vX+hXVlolhqskYFrd52HPP5e+DWBIAQ3YitIU+SJfOp6oyriNQzR4HXP1rPnAC4ArUueXGPvAVn3C/ex+FTEyqN2KTSZgaIqrElSrsMsoHG0HsOelOjiU89/pTAvlsc9xU2cN6D0rZabnO3dWRUvYRgZXIPU+lcJ4hTbKcDHFd/fMAPwrjfEEavCWBGar2mtjmq0rROWrX0RWMilAMjt61lIm8NgqMDPJxW94ZjMjHGMit5K6PNw+kjtrBfOAcgA9x6VcNkB/DUenxYUVtRxfIM800jsSMGIvMsSwhmlY4AA5JrRijfn5TleCRyM/WsUTNFauUVlLnl1PQDqK7rwZaJPaIZlzuGenY1yuDk9Do9uqSMXzXiYBwR7VMjh1LhuRXb6h4WE0DGFMkc7c8NXn91a3NkZPMjdVDbCT64zihxnSfvFxqwrx93ckIwc5P1piP5j+wqrHOQ5GeKswHbHweTya15rxOdwtKxp26DAHrUkiqvByR61BZ+Y+Cqsy9QcdakncElSNrL1zWSmmdcY9Cucbjjp6U+JS7AAd6QjPHWrdsoU89R2q0HL0NGxiVWDSHCj8amupx5e1Ooqg87KwC4x71qaNpVxqkoW2j3sx4qJ1EtjaMFHVmZIjOyLtbnpjvWg3hy/aNJPLdU25O6vXvCfw+htESa8UTXXUHstdTdaJE0JRox+VZezlPUxnmEIvlifLk0D202CD9atxzMsa7QAByOO9dx8QvDwsLkTRRjy3JyMd+xHvXn8mUbGQU7YopScdDqjUVWN0TvM0j7nbec4GaSLUZbOOdbb5WlYbm9geARVXzDuB7+hqG6IVwQCec5FdF9LkPsPUlcjJNEoeVNiMc84A61FExYHrg9aswziKF4olxI/DPnJ2nquP60K0kSrpmfHaOVYw7toOMk9/f1qa3mySONw42nsangMjXUS8lN3T+tR30Wy/3AYzyQKwa5XdGvPd2Zs+H9H1HXriWDS7czzxxmVkU84yB/MiiK3/svXDDqlk8rwFkkt27Njv9OtQaRqcumXJmt2Y7o3RlSVk3ZHcqQcA4OParOoail81iY4pEkjg2XDtJlp2JYu2ccZ3YHXFdMYpoxblfyPW9C8U6VFoi3NnGGYt5NtbgbIoh6ehYj5iferln4zS50LU0iEcOoW1rI7YbCR4+6f1zXjl34hhMElqtlGkChjbRIx2xFiMt6k4GM++awRKxDFXKluGw3UVjO0NDOOGU9WbdmltPbIk00kt3IDvkkOcHfk4z7Dk+9Z9yixyum4OFbAZeQaqJcqARuBz8vBpMkNjOKz50ztcGTq+eGGcdKiVVAdpDlhkKPxpkjgKSD83pVYykJjI4z2rRNdTmaaZft7qSByYHaMspQ7e4PUVKsuVC8dayUkxznip0l2ncxOB71PMaxgdJeateXOm2lndXLyW1rnyYz0WsczAbg4Iz61UnvcqFx8uPyrPmuWLbtxxSnUvsbwp6aliSYGdmBz2qCRgzECq4l3U0uVOe9ZQd2FaKsRH5ZhnscU6R9pJJz3qu0hMpI65pkpaRxGmSzGt29DhVo6voVtQlYxkqGJP5VyOpzv5box9/8K7LX0+wWJZuAB+ded3ty08hJPHpV04XPOq4htNsfptoLuVkLYwM1q6AfseomNycE4PvUfha386WdyuQm0fnWtLZbLguB3zmu6SvDQ4KMuWpqdxYBSikVtW4QpzXJ6RcnylVuCOK3IZztznr1rCE+h6mlrnJPdSGNoJlAIJPTGa7j4f6gGhVGZcqRGVzyB2OK8m1e7vTKJJHwc8BRwK0vCfihLTWLRbi3VFkdUZ1PHPGcVlF63Rz1W+S0lqfWWnQFoQw5yK5Lx14ae6geS3+V8AkdN2PWuv8MzrJZxMMYIrXvIEmQ5AP1r0XBVIWZ5cK0qM7o+W72F4JfKnBRgQDnsKtxfvMKjKCZBHj69/pXqPjLwrFeozxx/P7dq8m1yN9DvIFvSUwy/OeFODxzXBOlKlvsetDFRrarc930fQIZtLhDopKoBwMVx3jnw81kRcoCOcNgdvWvUfBf+k6XDI3BKir+vaPHe2rxyAEEGqlh+aPMtzmo4t056nzekqjJDAVYSb5d+ePQVP4j0G50m/liKj5iWXAzuH0qjYW00qj9y7HcFwqkn8a4nVtoz3Izg1zJnR+FNIk13VFt4xkDDOa+jPDPh610uyjSGJAyjJbHU1yfw10W3s7JJ4Y9jSKMnH3q9PgxsH9K0oR5vfkeVjMS5vlWw6NMRhckUkke5cDpUooNddjhuef/EPSDd6a/wApJQZGK+edYjEc+NuMEjgV9Y62okt5FwORg5r5h+ItiLLWZYkwVB3Dtwa5ZQUXc9PA1teVmArcrkfMfbrVG/lwcZ4zkCnpJ8jEsfl9P5VSvZFYYPykDpnvVvWOh6Kl7xYhnxG2eM9MetaCaijaYloLe3GJTMZ9n73kY2lu698etYPmOFAz06kCke4SOPdI6BV6knpUcziXaL3N60lWO4EjYVcZI9ahv723lkULLmQ84rlLjxDCXKRAOSOMN1qCC9dH8wqCSMEdaUndGHOnO6OxiO5sdyOfp61aDkcBvvA/jWPYXay226Ns5xwOtWzL1GBubgDPIFUpKKN/iJJiWyRyOnHaq+pO1qvlupSXAwp64xU0bFpdtrF505JIVeQPqatr4YvJbVr+5cPOzZKZ/Ekk9foK4atZM7KEYxac3ZGJaSKNwlBYkdfQ1o3BVUDKctgY96s3eiyWeniSaMCeRsgH7wGM9KxHuGeNOQGTjBHSop1EbVIqb5o7ErzEHJ4z71DLLgYHc0rKWIVsRvjPznbxVWRuMd84rsirK5wzs2WI5cDn+VRvcndgE1CXwmAagIaQhQCT2HXJrOU7FpPoF7fMmFiG5j1J6Cm23mzRl5CSB7YrsNK8DTTxrNeP5akA7FHNWF8PhNQnWW322kaqEOeCe9Ztt7IxdeCk25XscwqRLbK0cm92HK+ntVOR8DOTWlri2lpO/kjax6KOn1rDlnLH+vrW0VZERrc129gDYbI6muj8L6YJCbuYcD7uawtNspL25SNFJH8Rr0SO3WysCrAKka5Oa6KNKUnseZi8Qn7sTyz4nXmbiKzgHJyxHsK4KKKNk3PIUAIB+XNdDq13Lqeoz3McfDsY0kP932rd0bwXe6hqGnaUFhWa7lVYzvwCx6EntW9JN6JHNUhZXbLGgWdqunxR2KOUJ3PIwwWP0q1cWxYsm0EY6VZu7DU/B/jSXwxqUNvHJbr5skzSllZSMhlOOc5FaEqxyvE8bDy3x83au6VpQ0OOkmp6mVNYpZJbyQ3kVwXGXRVIMfsc9a0bWZmjG7A9sVNcWYjumQYbB6joakjgCj5OK4pRd7o9SnorFmw8AWN2FmvVd+4XdgVFqPwv0y9nX7MrQRqcsYz94enNesRWQeJIY+CRjitmHSEtrbaByRya6Y04WskeXUqzk7tmR4Jl8q2NqxJMRwMnnFdpy0WR3rz6ef8AsXU/OKFoW4cDrj1rXl8faRZ2u4Eu6jhCD1pxqQh7smZSpylqkV/iH4ks/CehT39448w5WGIfeduwr488Qa1e67qU17qEzPJIxIUn5UHoB2Fexa3o+r/FnxeIopTDCgyuRmOBPUjuTXuvhf4L+DNK8PLp91o9vqMzD97dXKBpGb1B/hHsKz5vbP3diuVUt9zmP2e/EsOreB7OASA3NiBbzJnkY+6fxGP19K9fMiyL+FeB/Ef4c3/w2kHi34aJLBbQoft9g7NIjIDnfgnJHqM5HUY5qz4W+PPhu/gjGqmfS7s4DLIpeMn2Ze31Aq0+XRkNNu6PTfFOl2moRIk8COyHehIGVPqDXO+GNOto5rmJ4lL78AnqKydZ+LvhC2hEjavFMxzhYFaQ/oOPxrnfAnxR0XXPGpsraG6t3uR+6kn2gSMvOMAnBx0+lcNeknPmsdEKkkrM+hNKj8qNFXAUcYArpLYkqDuz+Fc3p8okiVlPbkVvWEgK4qlGzsTzXNAUjUisDVLWdRttL066vb6ZILS3jaWWVzgIqjJJ/CtCjD8aa7YaDpFzqGqXEdvaQrl5HOAPb3PtXxX8RfitL4h1xpdMtvJs0JRS5+aVfUjt9Oag+N3xRuviFrZjt98GhWzn7NCeC/bzH9z2HYH615jUcie5UZuOsTv4/HFsIgz2kvndSAQVz+dVZPGrSvl4GUA8Ywa4qijkWxv9bqdzp9Q8VzyoUtlK5/ift+FYF1eXF0c3Ezyc5wTx+XSq9FNQjHZGc606nxMntrmSBgUOQDnB6V0VjrtoV23MbocfeBzXLUU3FMUaso6JnXPrVvAd9tcMG9gRXW+ApB4s1FbAXjLP947uMivJK3PBfiCbwv4lsdWgjEpt3y8ROA6ngj8unvisZ0FJWR0Qxs4u59faB4Mt7WFESHMUbYJcffx3/PNdCNGgNs8V3GGVugBwF9MelZXhL4p+E/E1pAthqMcV6wGbW5PlSKcDjB4bHqpIrpL66jkU7HGewrB4SMVpqaLGTk9WeeeJ7KePCwQPKjIVHPKc9j2yMV5F9oMEty8FurTH5fMkGfL/AN0dM+5z7V7trTxrazS3YaSFFLOgBYnHPAHJP0r5Y8e+NTq93La6PE1lpinAGNskh9W9B7fn6VlTwklK6O6OZRpwakr3Nx53ZiXcn3Y0y0mgu7g28NxDJc9olcFmPtXl5JPUmnwGRZUeFmWRSGVlOCCOhGO9dfsElucrzKTfuxPWnsb23YGS1mDEgKNueTXofgvwcVvUvbiM7ByiSDlfr71b+Fl/Lr/h+B9ThKalCu2UMuC47OB79/evSbGAKMEYApQwl9b3QVsylKPKlbuUl08KhKqBXLeJRFbW0ruVVUBJJOMD1rudQnWKFvpXifxXvJdRtX0q1mMbTcysOcL/AHfx/lW04Rgjjpycnc8V1zWJ7/XZ7u1mkWLOIv8Ad+nv1qr/AGhfbt32iQNWufD81lLsnXdGfuso61Y/stvLOIWP1FYt62SO2MNLtl/wf40fTrlF1SBZoehkjXDD3I71ueNPG1rqWnPZaN5zvP8ALJKyFQq9wO+a5BbBz/yyH0q3aWRJwoAbrhu9aKrUjHlSJ+r03LmI9Ks5JPLjY7iowAe1dZpOyG/gcyFTCwYHOOR6elZ2nw7FY7SGPfPSrsKKjqWXK56Z61MG4WZ0Sppqxe1XT7nxf4qlu4ba/wBSuWXe2zMkgUDufQVbkRRaRQmPaseQMdceldZ4A1aTRrLWr7TZhb3cKL5bbQSynquD9BWBL+/3SNkl2LEn3NelTS5W+55k4v2luxFd2LWcNm5kSQTxeYMHlfY01EzUiw8jOT2B9Kk8o4zxWUlqdMVZHteiWeQJHFWtevYLC0aSZ1UAcZq0jx2lm0jkKiKSSfavE/FPiGbXNSkIbbaqSI19R61FSp7KNluzjw+HdeXki9rusxXu8KCx7Y4AripNKuLuXy0lcvI2FQGtCNskhecDkkV1Pww0o6l4glupcmKABQO2a5eVSactWejOEaEG10PRfhD4Oj8N6Coky95cHzZnPXPYfQCvSIotuB2qGxiCRqoHatJcAc12R91WR4knzO7K0sKXETJIm8OCpUjgj/8AVXwl+0D8PR4E8ZMbCNhot+DNanHEZz80efbqPYj0r7skcRMWHI9K89+K+n2OueGprDUbaOeOZ1RAy5KMTgFe4Iz1FEmrajSdz5C+G3wv1nxvIs8QFnpIYq15KuQ2OoQfxH8h79q+ivD3wE8JaXBDNILy7vonEiXMlwyFWByCAmB1ru/Cuh2mjaXZ6bp8Xl2ltGI41/mSe5PWutS32qMdBVQjG2pE5SvocHqt9qXhqBruzs7rUki+ZobYr5oH+yrEBvpnP1qXwV8VvDniXMdrqUUd4Dh7W4/czKR1G04zj1Ga7GeIZdcDDDB4rzPUfhzoWp+KZ9TbS7Y3asCJGQZY9dxHTd79aicLfCEZ9z1hdXiSPe0iBPUnAr5g/aZ+KV9qdnL4b0iw1C10p5ALm/ngeJbnHOyPI+5nv3x6dfdtN8NOjAhR7ZrpItHtWtmhvYI7hGGCsg3A/gamMX1L510PzOPWkr6z/aB+CWgw+GNQ8SeFLVdMu7FDPPax8Qyxj7xC/wABA544PPHcfOHw68N/8Jf420jQTMYFvZtjyAZKqAWbHvhTik42KUro51QWYKoJJOAAOTWtcaDdx2iXEcVy6H72bWRdh+u3H61+hPgzwP4d8K2aW+haRa22FAaURgySY7s55J/GurEEZXaVGPTFVZLcnmb2PzPsfDGpajbGXTVhvCBkxQSq0ij3TOf0rHljeKRo5UZJFOGVhgg+hFfpPrngbw1rF1HdalotjPdR/cnMQWRfo4wR+deMah8AtGufiu2pXNzLNoroLprF8sS4IBUuTnZ0Pr2zRLlsrAnK+p8kaXpeoatci30uxur2c/8ALO3iaRvyANdRc/C3xzbWrXE3hfVBEoySIdxx9Bz+lfoLpWnabpFnFa6XY29rAi7VjgjEaqPQAVcKgj0pqKDnZ+X08MtvM8NxG8UqHDI6lWU+4NRV+jPjHwT4d8UwGPX9Itbs4KrKybZEB/uuMMPwNfKXxo+Cc3hKW1vvDLXF/pt3MIBCw3SwyN90ZHVT0yenGc5qXGxSlc89+HvgnU/G+s/Y9NXZBFhrm5YfLCp7n1JwcDv9Mmvrvwv4RbR9IjsrD7XNbW6gNLPIXYn1JPT6DgVY+DfgiPwb4LtdPba19KfPu3HQyEdB7AYA+lej28JWMoCQhOSOxqXFSFzO5xK6I7AEqc+9eS/GH4Rrq+n3GqaLaqmsxfOyp8ouFHUEdN3oe/Q19L/ZxgjHFU7y0V1I2jBFNRiguz88tI0Fbl9tyzxyKxWSMjBUg8g+hr1nwh4VsYY1e3ii3nrI3J/OvQfiZ4Qt7HUTq9nAiiY4uFC/ePZv6GsCyiMWHt28s4qIw1vLU9KnBTh7mhuar4d1HwndW17bvuJAZJ0GY3BGSue/uK6zRfGNjeqq3sX2aYcMM8H6GuZttWNzbRWd67CNSSqk5UE9SPSrw8Pgp50RVhnoKbm4v3DGdG2kyPxtrfnQGHSJVMmeWK7lA9vevMYrCeWcmbdI7HLM3JJr1ZPD7O2NlNfw6tqCzL+lYzjOcuZig1FWR5xdadiGPcoLbuhqpfWoCH5QOK6/xDZuZUEJA2jJFcxeD5dp5IFJz952PSoU7wRzEkQRywGMdai2ruyetXZwQ5z+AqmwzIPajmZfs0mTwKOnY1aSEOSUZW2nacHOD6Go4FwcVsafBHGreWqqGbcwUYyT1P1pxXM7MOay0LFhui067B4D7QfXrVtYiI+eR/ShvLhgijdd28lzz+VWTkRBhjFd9N2Vjia5pkMMRaNnBHy9qase8+gp6ryTzz+tTQxgjpWcmdCidh8SfESW2liwtpP3s/DYPRe9eSLP8x2c9hTNQvJJmaSVi8hPUmq1u+XB7159So6kuZnRQoKjDlOkt22WLDBLN3Neo/ByAR6W0oXmSRiST74rzCBVMUfrkCvXvhqgh0K26DJI/WuiG8Tjxj9xrzPULU/IOKsPJgdqzbebCiszxN4gh0fT2mkOXPCL3Jroemp5UIOTshfEPiCz0tD9plRWIyFB5NcJe+JINYubYIpWNZlIBGOc1wupahLqd/NcXDlpGb8h6VbihkiltXjJyWDH865pSnJXWx6kcJCMddz3DT4/lQ47Vrj7tZWiyB7WInklQa1WIHOcV1J6HkyjrYr3A6561SslVbuQ9yf6UmrajHZQPLKwCgd6xdH1y2vnE1u/BbawPUGs5VUpJB7GTXNY7q1AxUr1Us5wVB3DNTTSgLnNavchRMnxHbW+o6Te2F8oktbmB4Zk/vIykEflXzf8EvA9hofxTmuRFK3kpKbPzWyU5256D+EkZ+tfQ2sTwOrRzTx26suGlf8AhHeuWub+01Lx1pv9hxvMLS1MDMFxuQdx3IHFYVJanTTptp6HptsQVBqz2rLspx5anPNW/PGK0epjaxLK2BXOSgtrvnEjasGzHuWz/StHULxYomJIGPWuV07V0udVnjVgSSAK5q1Tlsi4029Tr4znFT9qoWsoIPrVwOMVpCbauS4WIpxnrXKeM4lm0a6hYDLD5CTjDA8H88V1Vw2BXC+OJ2NoFHEe7r6n0pVJdDSlS5pJG14XvC9tC7bS4GGHvjmujRfm6dea8b0XxA9jqEYIxC33wT0r1jTrkTxI6tkEcc1Cm1KxrWoOGppAACq1wvFWQwNQz/drZnNY4nxzZLdaRcRkA5UivI9ISJ3linYKXiJiZv7w/h+p6V7J4skP9n3AH9w/yrxW8jP2dgnDxHKkdamEtWenhV7ouoILeNT8vz5wAckYOOa3/A+st532S5IKfwH09q4cXJljJY8jtUdvcvDcJLE2GBzmsasmveieg6KqRcWfRdvCjqGAHSqWsWgaA5FVPB+vQajp8RZgJQoDLnvWzqNxEIjuI4Fbe1jKN0zxXTlCdmeUeJLf7Om8cNk7vp2rhNR+c5/lXZ+MZ2aSXk4c8j0FcNePt+9nOOK4rnu0Ie4mZF4KpKMscdRVu7YEdaZBH8475NUpBKLuWLdMqDitrTYXknhhQfPIwUYqlaQgZ38rW5o+6AvdrxJ/q4eO56n8q2p6swqaIdfRp9ukWM7kT5EPqB1qwyfIE7YpYozuGOvXmpZAAD1rqUtzOFMrRKA4IOcHNXlVWACjkdaqoOat27bc1k5m6geZ3EhkcsT1psUgjkBbkY4psm5Gw350hwy8VxLzOmotNDqLKcbI2J4zXqvgieH7AkErnhty4P5c14fYXTKmzPPpXW6BrHkplbgRMOgIJB/wranLocWIoua0PeZdUhsrQvI4CIPXpXkfijX/AO1r55biRo7deEUc8VQ1LxBLdx4lmLDP3AMD/wCvXL6hdlwB0J6VrOdzGjh/Z6vc1bWdJJXAJD9cGvTJr6y1H4eWzJAF1KxKwyOqdVLcHP8AnvXh1rdlJQc/MTzXe6LqkiWNxBFcGKO5QJIAM5Gc4/MUU5J3TLqRu00eveFNQD6ZDuPzqoBFbN7qqQQPLK4REGTzXkOk61Np7OsvMR6MDUGseI7vUI3hACQex5NUqjUeXqcrwt5X6FrxT4ifVL5hvP2ZThV9R/jVEC5trJdbi2eVFMsRIYZBPIBHoQOtc2JXecKSOtX7W8ls4L2Bhut7uMRyD6HKt9QelTGF4u50O0bRR7j4b16K9sI5o2GCORnpWpNqaMjbH5HX2rwHQ9dl0qRwpZoj2BwCa27vxjLJCFjbYW6554qo1WlZ7nPLBvmutjR8b+JDPdG2jJMQ4Yg4FUraX+wru0vrbUoGmjXehhO7BKk7Wz+RHvXHapfGQFh1JzUFlO0sRGc4pNq7R2xpWjboe/8AhTxANT02K4kIWU/6xR0Dd8e1bzagoQnNeB+H9alsc7dxXutbepeM5TbtHBkMRjPaphUcVytHLPBty0O11bxX5N99nt7VLyeT93Gh5AY+3euV1m11DRrqRri6iguljEgWNwxOeMcdDxXFzajNbnzhI3nHkNnkZrNh1UlmEhJyT3ofLb3tzphQ5PhPY/AnikXjfZ7kss/XJ6NXokVwuBzXzPY30lvMs0JKkHORXr2ieIEn06GWRwG2/N9e9Z05cnu9DnxWG15onX314qI3I4Ga4pEj1iz1nULycpa2ICwrngueen5D8ar+IdeiMLqkmM8E5rjptYNvoU1oD8kk/nsc9cLgD+dXF80rvZE0qTirrczdT1VH1ElSFUcAD0Fel+AddLRxwSMdpHy5/lXgrTme8dw3Q5wa7bwpqZQLtfDKeD1rJ+87nVUgpR5T6JjmBGc8Uy4lGwjNcxpmspLboxYA4wanvdSGw4rZ1UkeX7F3sYnjK+CWUyZ+ZhivK7uUJbMScE966jxbf/aJfKX6muD1m6Cw+WpFZwbim2epQp2jYz50MDIcgpKu5T+JGP0rS0PTk1Wz1XE0cU1rCJ1DtjeAcMB74xWJO52rknAqFbgKjkMw3DafcUSkk9djrinJaHQaLqsllMDE5HABINdgfFMnkfM27jvXlkU5VuOlTtfMcjPH1rjWjujWdCM3do6DXNVe9kQsRlfXoK5zUZSz5L7jjk1BNcHOMknr9KrEmRuelVdvQ1UVFEYQzS9DtFX7WAbwSKS3Tb05xWlbwtI6oiku3AA71rGNznnIVItxA5wfSty3hOF4wAMKPSrNp4fu2s2uo7eSSGLmSXHyg98H0FSwYUYxiuhRcdzD4hoj2ryeagk5yBzVpsNmovL524xjpVN6FxiRIOaljGFx0PpSqueecdKljXcMlQ3aody0jio/sWpW4DDbKo5Fc/MoSZkB6HpUkTtA5ZDgkYqFyWYn3rOUua10EIct7PQQAj5s4x1q3bS7fxquRx0p0ZwwGM5rNrXQu+hqrOxGcn6VWuDuB6fjVu0hWRBgjNNuLVlzgVaTW5yzmtjGAKz54wa3NPvym0f1rJlUgncM+9NjYqRTbtqiYu+52seqHYCGHSopNSJBCj8q52OYkAZNP87awyc01UZXKixcTz+b5kcm0+lT22rTA7ZVBArLeYZOTg+lSxOpGV6+9NNrZmbSe6N5ZY5V3RkA+lRyKR8wI/CsvnJZTj6UO0hGQSOKbn3RaVtmWLx2YYzTdNuljnKFvbis6Qyk8nj3qOKNt2Qeaxc3e6OiMVyu52KtEw3K4UUyZkUFiwPcVhRSyoOT0qUzSN1Na+0v0MkrdSe4uC7delU93zE5Ofenup2h2UgHpxwTUWcPhjwe2alpvcFKxetrsIArdPSuhtNRZIGS3uMKf4TXIlSqlgQOcEdTUsEjKuD0pKTi9UaWUkdNLOXZjJLnPJ781lare70MY4H8qpvdMBx1rNnlLyZc5+lU530REkkOhQZYlhyeK3tFmMLA5xXOxMC4J+grXtGbfjt9KTaRnE9C0/WdoAB246mrVzr7AEbicCuXsYndPlI3e9R3MbqSWICjvmq5xckG9STVdVxvcN87DGc1xt7O7yAsec8VqaltKkjk1hOCz7nyMdqym5Sep1U0raEjzbkHGDjvVZjz15p7KWBI6AUx04BxzUyRvTtEAcEknIpu/BJ7UmGIx1pyx88jmp5S3JDj8wz61atId+A2BmoUU5OANvqauxgg4HP4VSRlJ3VjV1BdPM0I023eFVQCQu+4u3rVvTpDb3CSiMNgdDWZb7eMjBrYt4tih2yBjgVum27owaS0Z1MXie+vbD+yZZY7exYZfYmDtH8IrJjAHXgds1VtWyGJxzxj0q6VzEw75GK05mxRilsNQAnHvyKnSEleQco3XFRqdpYHIwRnjmrvmFdrN94n7tBZX2pHLhlJHXI71WZ0jyScEn+E8GrNw67QykhuhH1rI1O+W0IRMOc8+gotcic1BXZ52FYuAASScADrT5IDFuEvyupwV71Y8sR4kf8AAdzUErGRi36CsDVO5GfmNSomBnFMVe/ap42XB3dhUjktCxbvt2jdirzznYVODWUCBwOvvTt5xgH9a0jIwnTuSTqr5+UYqs0Q7DpRv45P4URsckDIHoabaZPs2SxFE+8oxVhxC0Z5wapvksCMgfzqVORt3ZOPTpSVgdPqVrgDflRlf50+CRUPTA9KkMXPynkd6asG4jJwM80rNFcie5YSVOx4NS/aQMhRmqxhw3HXPTNObIXHQ+lK7GoIhnmLsc9PbtTA+GBPA7U7y8gnvSBPmxjj3NTY3SWxcjuA0fzj8anikRs84qtDDu2qOSxAHpmnFTG5DAqykg+1UrrUxcE9i+bqBLNoliYzscmQyEAD029/rVYmza1febkXe75cBTHj375qk+Wbdzn3poU4wM/nVc7ZHsrFx4Lcxo0U7tKT86lNoUfXPNCnYcE8AVUQZ5BbPpSMdp6kn+96VNy+XpcluZFHQ5/CqMjGRiEOPentl+T0PapYYSSAASTU7lOCW5LZQOSqE4966G3RY1iwwyTjeelYqI+7HQ/nVqFiV+Yk4GMf1rRQS3M+W+x0C3yxrt+6R/EOlUL6+MqbTwD3zVTJIIH3euc9KrTlWT36jFD2CNNXI5Lkq+1iWTtTWXc3yc57UwBXkGSR6+1Ptl3SHDde/tWSvszdxS1QggYSgZznrQ8IKsenNWmTG0tjB7g5pCsYGAfvVpYSZntFtGRg4oRWDAn0q+YeFXoT1p3kYPvjvSUQciukbDHOc881eiT91uzz0xS29sZ5FjU/Oxwo9T0x9asy6dc2lzJb3CPGyNtORkZ71qodTPmYttGrTgMpIOK7zTNLt4tNh1LUIHuYGm8lYEfbnjqTXM2VijOhFyp9wpOK3dP/AHLOt0wubUD5QjlSjeuK0jCxnOXMalvomi3Dy3AmmtLdeXiyGZBnsfWszUY7aK4lS3kZ4o3/AHbMMb0/xrbdzqtjp1jZ2UDtCxBlXCySg/3s9fzrI1W1mS5aKaFoXU8qw5GKtxutBRlrqV5I0CuYk8zcM7m5xUHM8W7zCjxkde5rZ0DTLrWZ57azhUuqb8lgowO+a5fUr7ymmjQ5bcQSBkjFTyjlVjG92M1C9WFdpA84+nauVu7hzIcctnnJqxdzH5t/3WGQT1FYd9eGMAIpLE5yRUt9EebXruQM28/NyT61AcjjODUxQryRkVEF3AntXMz3UrCZ49aemfbB65phGMgH8aEPSpGWH55HHakYEcHFMGB0OQKTqOelUZivgAY71MgxCBjD9M46ioUXLg+vT0qxE6SRrLGxZOVAx0IOD+oqkiHLoMQEqMHjPWpoI1IJyeeooCnG0Z29TipIUOdoGcjGD1FNRDmuhwQbcLk89elKgCEblySMjdUjgIm0dcUzcNmSRleOau1idxpZQCACD0NRlMrnqBSMC8nUjPpzxUnygjnjoMnNZvU0VkMgTIBIPXGelK0GGByOO1W4VEYjYqTnrkdamn2LGfl4OMcVSgQ56kEUELwFXfy5S3BJOFFdW2hrrlldRsqx65YxGUyxKBFdxAA8kfx4yQR1xzWLoNnLqtw9rAlmrIu8yXVyLeNFzySTyT7Ct+PRNLtgftvjDTEdTyun2sl0R7buBW8YraxhOrbrqcY9sUUtt5GOtVmAUksOTwBXof2Hwrc+bcz6v4gvWyN8hSCHccekjZplhpvhy5kZdNsfFt9s5fynttq/U9P1o9j2J+sLqjz8RnLYHXoKdHb7uXAC9vWt7xXawWd9GLK01C1QocpfyRs5PqNgxisRnAhI+XeTndnpiodNJ2LjWuroheBVYfX8qsLHjAHJA5FVIwz4LOBg+vWrtxceckW3bGEG07eM/WpUUtS3UHqpaNdvyg56UgO2QKAdpHPtTYJohKGdTtIxtBxg+tIZQDtX16iraTQlNXJSVAKhsH6dKj8slwvUY7U07stkYGeMd6kXfGxBZHJ/uc4/HtWbg2ae0XQiZApPsfypyKRHlVIbH3s96kYpt+b881Ihj+UMx2GhQH7TQoncWU4PuPWrkCgMxAG3rUg8tpcRsMZ/KrBiV3IRSNvVgOKI09dBupfQjiUM2DnnqfSneWfOAQ5FW0TYVkX94uMcDp9aiOxjxyynjHGPrVuDtqCkIsYUqT8vfPetUXs1xDBv374dwLsc7gccEfh1qvbxfK0020sx4FTny1bEjr6gZpx0JbTLK3MizIXIXaMZVcCrf2g+SdgVmbvWb5qSBf7oz+NMiZ/P2RrlTyDnitUupm2kddotxGI0dgHkQ4QZxtNXda1d7thcatMrTBCioFGSP8+tcnbTy2xJVtu72zVS6mMu9rgncemelO6RyVKkU7omvdTlPyws8MWNpVGwSPf1rnL24WOQMTypPI7in3155CnJw3YH0rnbi5lmm8yNd8Sn5g3RvasZSvojknVb1ZNf3kYgWWBw0nUxk7S3P3QP1zWau+WQ5XecZK/3aFgVbt3YDzHbc2zhQPQCtCCExoWXJdjztOKhytoY25tR93b/AGe4khEqTqjFRJGcq3uPaqjq2cdB0rT8tTk1FOoDfjWbj1PolN7FB4ztHGBUixfMo5BPtU4647U5FBcjHFCiS6jI/LKZ4yMdCKidSflCnJq4hyozzU2wEHParVO6uZOrZmfHDsKgNzzkHpVzhlGVYZHORTmUCTPfNSSDC5HUYq1ETmyk7mMBT3/MVagZgMovPcmoVG99zcnGasx8zKueMZpxVhOYeUxIkyCWOeaZcYY7SO341PJK3QAALwOKq7fO+8xGfSqkkT7RjDHuBJc4zgVIgXeEBUKozn1q7Dp1v+83KzbV3DJ71ftbSBZYFEagMCTx6DNRZJi9q2Z2A+BGruT7dae1rdzQgGPAHGWP9K14WO24XtC67fxGeagSd3eInH707mx9eg9BRdEc0ijDozySt5s6DHZV3c+lXUsLGNd/m3LkkhgSqAY69jzSrI3ny5IyjMQcc5A6/rTZBtDYzkvsY5+8OvPvRzCd31J3ttNaRo00/LlARI1wzkY5OBwDkdu1MtbBJpkSK2idnYkKASAPcGiKUxyxMqp8yEnKjH0/WpLe5miuV8qRo28wxbkODtxnGapMyZZntftchj+w2kXljegit1Qt7kgciqMVnE0J3xgBSRnbyTUhmlfZI8jFgp6n1bFRszKJGViGMmM/pTbuJETwQrtkWNCSdkgK/dPqPWhoo13KY1LAZ24HT1poP+jr6BcgehAPNMlYlEOTnYP161I7kjpBsjBVOGBZtoHynvj0qKVLfzWYqn3towOB75qPcWw5+8VJ/KoIx5hdWJIC7vxNLVjvYnaGEyfKfk43Acbc96jlt02uRkBX2YB5NPXnzG/ukYFRIzEEknKgkfXPWjUfOyJ7ZVBAYkqcdOB9aRvur8+R06d/SnPIzysrdDhj9cUxFA8v1ILZ9Dild9C1NjogyN0RdvUEZq3b31xC2bdgGHdGH8qzh/q+OARgj1qOQlNhB70lNotTudDJf3M8YMqluMEgAE/lVFEffkbwCfWsmG4lBT5zya07W5kZsEjqKtVObRj5mtjWimYR7ChH+2RV2w024u4C8oCxZ4Y9T9Kz9Jdp9XtreVi0W/lfXAJrudSjWOCHYMAtjAq001cwnXlHRHNpp1vHGpBdwG2t7VZESKjsQmV7Y5ZajuGIjlZflZmwcVSMzPIpbHAI4qebUwlUb3LF3IiDKHERXI3djWFe3khYEKcDqTT9TkcJnccg8VnXDlfNP9045qXK5k3cqXWZ5C0x2j+Yqq7r5gVkIhTgKnVjVmNBcOpkJJ5PFMnxGo2quQeCRUt2IGwoQ7SSs7YTGM9fb2+lS/Z2mJw5DKBk78DmoZGZXZQxwRk+9S3KBLG1nUnzJi278MAYqGxXP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_23_34175=[""].join("\n");
var outline_f33_23_34175=null;
 